Published in final edited form as:

J Perinat Med. 2016 October 01; 44(7): 813–835. doi:10.1515/jpm-2015-0259.

Characterization of visceral and subcutaneous adipose tissue transcriptome in pregnant women with and without spontaneous labor at term: Implication of alternative splicing in the metabolic adaptations of adipose tissue to parturition

Shali Mazaki-Tovi^{1,2}, Adi L. Tarca^{3,4,5}, Edi Vaisbuch⁶, Juan Pedro Kusanovic^{3,7,8}, Nandor Gabor Than^{3,9,10}, Tinnakorn Chaiworapongsa^{3,11}, Zhong Dong³, Sonia S Hassan^{3,11}, and Roberto Romero^{3,11}

¹Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel

²Tel Aviv University, Tel Aviv, Israel

³Perinatology Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, and Detroit, Michigan, United States of America

⁴Department of Computer Science, Wayne State University, Detroit, Michigan, United States of America

⁵Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, Michigan, United States of America

⁶Department of Obstetrics and Gynecology, Kaplan Medical Center, Rehovot, Israel

⁷Department of Obstetrics and Gynecology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

⁸Center for Research and Innovation in Maternal-Fetal Medicine (CIMAF). Department of Obstetrics and Gynecology, Sótero del Río Hospital, Santiago, Chile

⁹Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary

¹⁰First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

¹¹Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, United States of America

Abstract

Correspondence: Shali Mazaki-Tovi, MD, Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, 52621 Israel, Telephone (+972) 3-530-2169, Fax: (+972) 3-5302922, shalimazaki@gmail.com and Roberto Romero, MD, D(Med)Sci, Perinatology Research Branch, NICHD/NIH/DHHS, Hutzel Women's Hospital, Box No. 4, 3990 John R, Detroit, MI 48201 USA. Telephone (313) 993-2700, Fax: (313) 993-2694, prbchiefstaff@med.wayne.edu.

Disclosure: The authors declare no conflicts of interest.

OBJECTIVE—The aim of this study was to determine gene expression and splicing changes associated with parturition and regions (visceral vs subcutaneous) of the adipose tissue of pregnant women.

STUDY DESIGN—The transcriptome of visceral and abdominal subcutaneous adipose tissue from pregnant women at term with (n=15) and without (n=25) spontaneous labor was profiled with Affymetrix GeneChip Human Exon 1.0 ST array. Overall gene expression changes and differential exon usage rate were compared between patient groups and adipose tissue regions (paired analyses). Selected genes were tested by quantitative reverse transcription–polymerase chain reaction.

RESULTS—Four hundred eighty-two genes were differentially expressed between visceral and subcutaneous fat of pregnant women with spontaneous labor at term (q-value <0.1; fold change >1.5). Biological processes enriched in this comparison included tissue and vasculature development, inflammatory and metabolic pathways. Differential splicing was found for 42 genes (q-value <0.1; difference FIRMA scores >2) between adipose tissue regions of women not in labor. Differential exon usage associated with parturition was found for three genes (LIMS1, HSPA5 and GSTK1) in subcutaneous tissues.

CONCLUSION—We show for the first time evidence of implication of mRNA splicing and processing machinery in the subcutaneous adipose tissue of women in labor compared to those without labor.

Keywords

Adipokines; Delivery; Fat depots; Gestation; High dimensional biology; Metabolism; Obesity; Pregnancy

INTRODUCTION

Parturition imposes an increased energy demand on the laboring woman. Labor is characterized by increased concentrations of nutrients including glucose (1–5), free fatty acids(3;6), ketone bodies(7), and lactic acid.(8) There is an approximately 3-fold increase in whole body glucose utilization during labor and delivery and, as expected, energy expenditure of the parturient women in the second stage of labor is 40% higher compared to the first stage.(9) Additional support for the metabolic burden of labor can also be found in the examination of myometrial glycogen storage, which is significantly increased at term (10), but almost completely depleted during labor.(11) Consistent with these findings, examination of human myometrium transcriptome revealed that biological processes related to metabolism were among the molecular functions enriched in the differentially expressed genes between pregnant women with and without spontaneous term labor.(12)

The conventional view is that energy expenditure of labor and delivery are equivalent to that of moderate exercise (1;9) and that similar mechanisms (e.g. insulin and non-insulin dependent glucose uptake, enhanced hepatic gluconeogenesis and direct sympathetic nervous system stimulation) are governing the metabolic adaptation to parturition (9;13;14). However, whether or not adipose tissue, the major energy reservoir, is affected by labor and delivery is still unknown. Assessment of the putative role of adipose tissue in human

parturition may be of special importance considering the large body of evidence indicating that this organ is a powerful endocrine organ (15) that exerts autocrine, paracrine and endocrine effects by production and secretion of highly active peptides and proteins collectively termed adipokines.(16) Importantly, adipokines have been implicated in physiological adaptations of normal gestation,(17–29) as well as in the pathophysiology of preeclampsia,(21;30–51) gestational diabetes mellitus,(52–66) preterm birth,(67–69) delivery of large for gestational age (LGA) newborns,(70) small for gestational age (SGA) (71–77) neonate, pyelonephritis(78–80) and intrauterine infection and inflammation.(81–84) Of note is the well established association between obesity and these complications of pregnancy.(85–114)

It has been suggested that implication of adipose tissue in physiological or pathological processes should take into account the region-specific differences between fat depots. Particularly, differences in function (115–117) gene expression;(116;118–145), and metabolic effect(146–151) between visceral and subcutaneous adipose tissue are to be considered. Indeed, adipose tissue regional variations in specific genes were reported in non-pregnant individuals using both high throughput techniques (132–134;137;152) and targeted approaches. (116;117;132;134;153–167) Adipose tissue overall gene expression in pregnant women have been previously reported (33;118–124;168–181) however, adipose tissue gene expression, biological processes, molecular functions, and pathways associated with spontaneous term parturition have not been described. Furthermore, to our knowledge, exon-level changes that can inform on alternative promoter usage, alternative splicing and alternative transcript termination (182) between visceral and subcutaneous regions have not been reported in either fat or other tissue of parturient women.

We undertook this study in order to characterize the transcriptome of human visceral and subcutaneous adipose tissue during normal labor at term to gain understanding of global changes in gene expression and splicing associated with adiposity using an unbiased approach. The aims of this study were: 1. to determine differences in visceral and subcutaneous gene expression between pregnant women with and without spontaneous labor at term; 2. to determine regional variations in the transcriptome of adipose tissue of patient with spontaneous labor at term; and 3. to identify depots-specific alternative splicing alterations in adipose tissue of women with spontaneous labor at term.

MATERIALS AND METHODS

Study groups

A prospective study was performed in which visceral and subcutaneous adipose tissue samples were obtained from women undergoing cesarean section at term (37 weeks) in the following groups: 1) not in labor (n=25); and 2) spontaneous labor (n=15).

The inclusion criteria for both groups were: 1. Absence of medical complications; 2. No antibiotic administration prior to the sample collection; 3. Normal post-operative course; 4. Absence of meconium staining of the amniotic fluid; 5. Neonatal Apgar scores>7 at 1 and 5 minutes; 6. Absence of histologic chorioamnionitis; 7. Absence of obstetric complications of

pregnancy; and 8. Normal pregnancy outcome, including an infant who was of appropriate weight for gestational age (AGA) without congenital anomalies.

Eligible patients were enrolled at Hutzel Women's Hospital (Detroit, MI, USA). All women provided a written informed consent prior to the collection of adipose tissue samples. The collection and utilization of the samples for research purposes was approved by the Institutional Review Board of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD/NIH/DHHS, Bethesda, MO, USA), and the Human Investigation Committee of Wayne State University (Detroit, MI, USA). Samples obtained from pregnant women not in labor have previously been used to study the differences in transcriptome between pregnant and non-pregnant women.

Clinical definitions

Patients not in labor underwent a cesarean section secondary to a fetus in non-cephalic presentation, previous uterine surgery or classical cesarean section, or an elective cesarean section with no more than one previous cesarean section. Women in spontaneous labor underwent cesarean section due to a fetal malpresentation or for non-reassuring fetal status as determined by the clinical staff. Patients with clinical or histological chorioamnionitis and those undergoing induction of labor were excluded.

Labor was diagnosed in the presence of spontaneous regular uterine contractions occurring at a minimum frequency of 2 every 10 min with cervical change that required hospital admission. Histologic chorioamnionitis was diagnosed using previously described criteria. (183;184) An AGA neonate was defined as a birth weight between the 10th and 90th percentile for the gestational age at birth.(185) Body mass index (BMI) was calculated according to the formula: weight (kg)/height² (m).

Sample collection

Paired visceral and subcutaneous adipose tissue samples were obtained from each participant. Subcutaneous adipose tissue samples were collected at the site of a transverse lower abdominal incision, in the middle of the Pfannenstiel incision, from the deeper strata of subcutaneous fat. Visceral samples were obtained from the most distal portion of the greater omentum.(117;186–189) Visceral and subcutaneous adipose tissues were collected using Metzenbaum scissors and measured approximately 1.0 cm³. Tissues were snap-frozen in liquid nitrogen, and were kept at –80°C until used.

RNA isolation

Total RNA was isolated from snap-frozen adipose tissue using TRI Reagent® combined with the Qiagen RNeasy Lipid Tissue kit protocol (Qiagen, Valencia, CA, USA) according to the manufacturers' recommendation. The RNA concentrations and the A260 nm/A280 nm ratio were assessed using a NanoDrop 1000 (Thermo Scientific, Wilmington, DE, USA). RNA integrity numbers were determined using the Bioanalyzer 2100 (Agilent Technologies, Wilmington, DE, USA).

Microarray analysis and real-time quantitative polymerase chain reaction

The Affymetrix GeneChip Human Exon 1.0 ST array (Affymetrix Inc., Santa Clara, CA) platform was used to measure the expression levels in each unpooled specimen, per manufacturer's instructions (<http://www.affymetrix.com>). The array contains approximately 5.4 million 5- μ m features (probes) grouped into 1.4 million probesets interrogating over one million exon clusters.(190–192) To verify the results from microarray based analysis, 24 genes were selected for quantitative polymerase chain reaction (qRT-PCR) assays in the same set of samples used for microarrays.

Statistical analyses

Differential expression—The raw microarray probe intensity data was background corrected, quantile normalized(193) and summarized into one expression value for each transcript implemented in the *aroma.affymetrix* package(194). A paired moderated *t* test(195) was used to test for differential expression with false discovery rate (FDR)(196) correction of p-values to obtain q-values. Gene significance was inferred using $q < 0.1$ and fold-change in expression > 1.5 .(197) Gene ontology analysis was performed with algorithms that were described previously.(198) Pathway analysis was performed on the Kyoto Encyclopedia of Genes and Genomes (KEGG)(199) pathway database (96 pathways with 3 or more genes on our microarray platform) with an overrepresentation analysis(200). Alternatively the Pathway Analysis with Down-weighting of Overlapping Genes (PADOG) (201) was applied on the canonical pathways collection from MSigDB database(202) (831 pathways with at least 20 genes represented on our microarray platform). Differential expression between adipose tissue regions of the same subjects based on qRT-PCR data was performed with a paired *t* test on – Ct values.

Differential exon usage (splicing)—In order to identify differential exon usage between groups of samples, we used the FIRMA (Finding Isoforms Using Robust Multichip Analysis) method(203) to quantify how far (above or below) a given exon's expression level was compared to the expected (average) transcript level in a *given* sample. Criteria for inclusion of transcripts and exons are described in the supplementray material. We applied a t-test for each probeset (typically one per exon) in each transcript based on the FIRMA scores, and inferred significance when the difference in mean FIRMA scores between groups was 2.0 or more combined with a threshold of 0.1 on the False Discovery Rate adjusted p-values (q-values). This was a more stringent approach than described in another study(203) in which positive results were identified based only on the difference in mean FIRMA scores above 1.5 units. Plotting of the probe-level expression data at exon levels vs. genomic coordinates was performed using functionality provided by the *GenomeGraphs* package with known isoforms in the ENSEMBL database being retrieved with *biomaRt*(203). All microarray analyses were performed using the R language and environment and Bioconductor(203;204).

Demographic data analysis—The Student *t*, Mann-Whitney *U*, and X^2 tests were used to identify significant differences in patient demographics between women in the microarray and qRT-PCR groups. SPSS software (version 14.0; SPSS Inc, Chicago, IL) was used for

statistical analysis of demographic data. Probability value of $< .05$ was considered statistically significant.

RESULTS

Demographics

Table 1 displays the demographic characteristics of patients who were included in the microarray and qRT-PCR analyses.

Regional differences in the transcriptome of adipose tissue of women with and without labor

Differential expression—Microarray analysis demonstrated 485 transcripts corresponding to 482 unique genes that were differentially expressed between visceral and subcutaneous adipose tissue of pregnant women in spontaneous labor at term (q -value < 0.1 ; fold change > 1.5). A total of 329 genes had decreased expression, and 153 genes had increased expression in the subcutaneous, compared with visceral adipose tissue. A “volcano plot” shows the differential expression of all the annotated probesets on Affymetrix GeneChip Human Exon 1.0 ST array with the log (base 10) of q -values (y -axis) plotted against the log (base 2) fold changes (x -axis) between the visceral and subcutaneous adipose tissue (Figure 1). The heatmap in Figure 2 uses a color scale to show the consistency of the expression levels within each group of samples as well as the differences between the groups that led to positive test results. A list of the top 100 differentially expressed genes between visceral and subcutaneous adipose tissue of patients with and without spontaneous labor at term is presented in Table 2; the complete list of differentially expressed probes is available as supplementary material (Supplement Table 1).

Among the 482 genes that were differentially expressed between visceral and subcutaneous adipose tissue in patients with spontaneous labor at term 91 were not part of the 632 genes differentially expressed in the no labor group (ENTREZ IDs suffixed by a * in Table 2 and Supplemental Table 1).

In order to gain further insight into the biology of the differential gene expression, Gene Ontology enrichment analysis was employed. A total of 94 biological processes were associated with regional differences in the spontaneous term labor group ($q < 0.05$) (Table 3). Pathway analysis performed using an over-representation on the KEGG database resulted in 7 significant pathways in this comparison ($q < 0.05$): Complement and coagulation cascades, Cytokine-cytokine receptor interaction, Focal adhesion, Steroid hormone biosynthesis, ECM-receptor interaction, African trypanosomiasis and Protein digestion and absorption.

qRT-PCR analysis—The results of qRT-PCR confirmed the differential expression of 9 of 29 genes that were found to be significant on the microarray analysis: lipoprotein lipase (LPL), retinol binding protein 4 (RBP4), leptin (LEP), complement component 4B (Chido blood group) (C4B), insulin-like growth factor binding protein 2 (IGFBP2), monoglyceride lipase (MGLL), annexin A8 (ANXA8), klotho beta (KLB), and prolactin (PRL).

Differential splicing—Using the Affymetrix GeneChip Human Exon 1.0 ST array that probes individual exons of known genes, we have compared the exon usage (inclusion) rates between adipose tissue regions. Significant differences in exon usage were found for 42 genes between visceral and subcutaneous adipose tissue of pregnant women not in labor (Table 4) but not in the labor group.

Patients with spontaneous term labor versus pregnant women not in labor

Differential expression—We did not find significant differences in gene expression in either visceral or subcutaneous adipose tissue of pregnant women with and without spontaneous labor using our predefined gene selection criteria. However, when applying PADOG pathway analysis, 4 KEGG pathways (Spliceosome, Snare interactions in vesicular transport, Pathogenic *Escherichia coli* infection, DNA replication) and 3 Reactome database(205) pathways (Processing of capped intron containing pre-mRNA, mRNA processing, mRNA splicing) were found significantly perturbed in the presence of labor in the subcutaneous region of the adipose tissue (see enrichment plots for two of these pathways in Figure 3). Unlike the over-representation approach that requires gene selection as a first step, PADOG determines whether the differential expression t-scores of a given pathway are higher (in absolute value) than those of all genes profiled on the array and hence detecting potentially smaller but systematic differential expression in a given pathway compared to all genes on the array (Figure 3). When comparing the women in labor with those without labor in the visceral region, the PADOG identified the Reactome *Asparagine N linked glycosylation* pathway as associated with parturition (see Figure S1).

Differential splicing—Significant differences in exon usage were found between subcutaneous adipose tissue of pregnant women with and without spontaneous labor at term for three genes: Glutathione S-transferase kappa 1 (GSTK1), heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) (HSPA5), and LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1). None of these three genes were differentially expressed between visceral and subcutaneous adipose tissue of parturient women as the changes in mRNA abundance was present only for one exon of each gene (Figures 4 and 5 for an illustration of the differential exon usage for LIMS1 and GSTK1). For all three genes, the exon showing differential usage had lower expression in the group of women in labor compared to no labor group. These three genes were not among the 42 genes with differential exon usage between visceral and subcutaneous adipose tissue of pregnant women not in labor (Table 4).

DISCUSSION

Principal findings of this study included the following: 1. Visceral and subcutaneous adipose tissue transcriptome of pregnant women with spontaneous labor at term were different: i. 482 genes were differentially expressed between the two fat depots; ii. gene ontology analysis indicated specific biological processes (e.g. Cell adhesion, Vasculature development and Circulatory system development); iii. The KEGG pathways enriched in differentially expressed genes were: Complement and coagulation cascades, Cytokine-cytokine receptor interaction, Focal adhesion, Steroid hormone biosynthesis, ECM-receptor interaction,

African trypanosomiasis and Protein digestion and absorption. 2. Significant differences in alternative spliced genes were found between subcutaneous adipose tissue of pregnant women with and without spontaneous labor at term: 3 genes affected by alternative splicing: LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1), heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) (HSPA5), and Glutathione S-transferase kappa 1 (GSTK1); and 3. Visceral and subcutaneous adipose tissue transcriptome of pregnant women with and without spontaneous labor at term did not differ significantly.

Visceral versus subcutaneous adipose tissue in pregnant women with spontaneous labor at term

This study describes, for the first time, the transcriptome of visceral and subcutaneous adipose tissue of pregnant women with spontaneous labor at term. High throughput technology has been employed in obstetrics.(206–211) Specifically, transcriptome of uterine cervix, (212–220) myometrium,(12;221–227) chorioamniotic membranes,(228;229) amniotic fluid,(230–239) and maternal blood(240) umbilical cord blood(241) have been reported. Region specific differences were extensively investigated in non-pregnant individuals using both targeted and high-dimensional biology techniques.(125–143;146;149–152;154;242–245) In contrast, previous reports concerning gene expression in adipose tissue of pregnant women have used only targeted approach(33;118–124;168–178;246;247) with only two exceptions.(181) Resi et al. investigated the transcriptome of subcutaneous adipose tissue obtained from the gluteal depot. Participants in that study included of healthy non-obese women, not in labor healthy women.(181) This is the first report to use either high dimensional biology technique or targeted approaches in the investigation of fat depot during normal human labor.

Bashiri et al(248) have determined alterations in genome-wide transcription expression in visceral and abdominal subcutaneous fat deposits in obese and lean pregnant women (4 in each group) using Affymetrix Human Exon 1.0 st platform. The authors reported that global alteration in gene expression was identified in pregnancy complicated by obesity and the identification of indolethylamine N-methyltransferase, tissue factor pathway inhibitor-2, and ephrin type-B receptor 6, that were not previously associated with fat metabolism during pregnancy. In addition, subcutaneous fat of obese pregnant women demonstrated increased coding protein transcripts associated with apoptosis as compared to lean pregnant women. Of note all participants in the study of Bashiri et al(248) were not in labor.

Comparison between the transcriptome of visceral and subcutaneous adipose tissue in pregnant women with and without spontaneous labor at term: evidence for an active role of adipose tissue response in the metabolic adaptation to parturition

An additional novel finding reported herein is the implication of alternative splicing in subcutaneous adipose tissue of pregnant women in spontaneous labor at term. Alternative splicing is a major biological process by which a relatively limited number of genes can be expended into elaborate proteomes.(249) It has been estimated that approximately two-thirds to three-quarters of all human genes undergo alternative splicing.(204;249–251) This process allows cells to include or exclude different selective sections of pre-mRNA during RNA processing.(252) The altered transcripts result in closely related proteins expressed

from a single locus.(252) The splicing process may affect function, localization, binding properties, and stability of the encoded proteins,(249;253) as well as degradation of the transcript.(249;254;255) It is an important regulatory mechanism that has been shown to be involved in several molecular pathways including angiogenesis and differentiation.(252;256) To our knowledge, this is the first report implicating alternative splicing in parturition-related differences of subcutaneous adipose or any other tissue.

While we did not find significant differences in gene expression between either visceral or subcutaneous adipose tissue of pregnant women with and without spontaneous labor at term, we identified 3 genes affected by alternative splicing: Glutathione S-transferase kappa 1 (GSTK1), heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) (HSPA5), and LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1). The Kappa class of glutathione S-transferases (GSTK) was first identified in mitochondrial matrix from rat liver.(257) Human glutathione S-transferase kappa 1 (GSTK1) gene and protein were first characterized less than a decade ago.(258) Further studies of human GSTK1-1 have confirmed its presence in mitochondria and peroxisomes.(259–261) GSTK1-1 is highly expressed in adipose tissue and its expression level was negatively correlated with obesity in humans and mice.(262) Importantly, GSTK1-1 plays a critical and selective role in regulating adiponectin biosynthesis. Specifically, suppression of GSTK1-1 results in inhibits adiponectin multimerization, probably by functioning as protein disulfide isomerase that regulating adiponectin disulfide bond formation, which is essential for multimerization.

Adiponectin, identified independently by four groups (263–266), is the most abundant gene (*AMP1*) product of adipose tissue; it circulates at relatively high concentrations. (267) Adiponectin has an important role in the pathophysiology of insulin resistance and diabetes (268), atherosclerosis (269), hypertension (270), dyslipidemia (271) and angiogenesis (272). A solid body of evidence supports the role of adiponectin in normal gestation and pregnancy complications: 1) circulating maternal adiponectin correlates with insulin resistance indices during pregnancy (273); 2) patients with gestational diabetes mellitus (GDM) have lower concentrations of adiponectin compared to those without GDM (52;54;274;275); 4) overweight pregnant patients have a lower adiponectin concentration than normal weight pregnant women; 5) preeclampsia is associated with altered maternal adiponectin concentrations.(21;30;33–35;37;39;47;276) Collectively, these findings suggest that adiponectin may play a regulatory role in metabolic and vascular complications of pregnancy. Adiponectin circulates in human plasma in distinct forms: 1) low-molecular-weight (LMW) trimers; 2) medium-molecular-weight (MMW) hexamers; and 3) high-molecular-weight (HMW) oligomers (12 to 18 subunits) (277). These adiponectin multimers can exert distinct biological effects (277), activate different single transduction pathways (278;279) and may have different affinities to the adiponectin receptors (280). Consistent with these findings, the ratio of HMW to total adiponectin(277) has a better correlation with insulin resistance (277), obesity (281), cardiovascular diseases (282) and other impaired metabolic states (283;284) than total adiponectin. Alterations in adiponectin relative distribution of adiponectin have been reported in normal gestation,(17;22;26;285;286) as well as in preeclampsia,(32;287) gestational diabetes,(53;288) and delivery of small for gestational age neonate.(72) (17;285–288). We have previously determined circulating maternal adiponectin multimers concentrations in normal pregnant women and those with

preterm labor, with and without intra-amniotic infection/inflammation.(67) We have found that labor, *per se*, regardless of the presence of infection/inflammation, is associated with significant quantitative and qualitative alterations in adiponectin multimers. Taken together, the results of our previous and present studies suggest that difference in the subcutaneous adipose tissue expression of GSTK1 between pregnant women with and without labor may provide a molecular mechanism for the altered regulation of adiponectin and adiponectin multimers associated with labor. This, in turn, may be important for to regulation of energy expenditure associated with parturition.

Heat shock 70kDa protein 5 (HSPA5), also known as 78 kD glucose-regulated protein (GRP78) or immunoglobulin heavy chain-binding protein (BiP),(289;290) is an ER-resident multifunctional molecular chaperone(291) that belongs to the Hsp70 family of heat shock proteins.(292) HSPA5 is a key component of the unfolded protein response (UPR) signaling pathway that plays an important role in ER homeostasis.(293) HSPA5 increases the ER protein folding capacity by forming multiprotein complexes with other ER chaperones and regulates the activity of the ER-transmembrane sensor proteins PERK, IRE1 and ATF6 by sequestering them in inactive complexes.(294;295) Recently, several studies proposed that increased endoplasmic reticulum stress may represent the proximal cause of the association between obesity and adipocyte insulin resistance.(296–298) Moreover, studies examining human adipose tissue have indicated that there is an increase in the ER stress transcript HSPA5 as a function of increased BMI.(299;300) Thus it can be hypothesize that parturition imposes increased in metabolic demands and results in ER stress which in turs is attenuated by overproduction of HSPA5 in subcutaneous adipose tissue. Further studies are needed to test this hypothesis.

Additional gene affected by alternative splicing in subcutaneous adipose tissue of pregnant women with spontaneous labor at term is LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1). LIM domain proteins contain at least one double zinc-finger motif and they expressed mainly in mammalian hearts, particularly in cardiomyocytes.(301) These proteins contain between one and five LIM domains and have been implicated in the development of the heart and heart disorders. There are two members in the five LIM family: LIMS1 and LIMS2. They act as adaptor proteins forming ternary complexes and participate in cell–cell, cell–matrix adhesion, migration, growth and cell survival.(302;303) LIMS1 and LIMS2 also function as stress sensors that enable the heart to detect mechanical stretch and respond by increasing contractile force. Other members in this large family have been implicated in the development of the heart,(304–309) kidney(310–312) and liver(313) as well as in cancer(314–320) and in neurodegenerative disease.(319;321) Interestingly, a member of the LIM family, four and a half LIMs domains (FHL1), was found to be differentially expressed between visceral and omental adipose tissue in humans. To our knowledge, this report represents the first evidence that LIMS1 is expressed in human adipose tissue. Based on previous reports concerning the physiological role of this gene in other organs, it is tempting to postulate that LIMS1 is involved in the remodeling of the subcutaneous adipose tissue.

Strengths and limitations of the study

Major strengths of this study are the novel findings reported herein, the implementation of high throughput technique in the investigation of different adipose tissue depots, the evaluation of paired specimens, the inclusion of well-matched controls and the relatively large sample size. Our results include the first description of the transcriptome of adipose tissue visceral and subcutaneous transcriptome in parturient women. Significant differences in alternative spliced genes were found between pregnant women with and without labor in the subcutaneous adipose, implicating alternative splicing in labor-associated differences in subcutaneous adipose tissue for the first time. We have identified the LIMS1 gene previously unrecognized to be expressed in subcutaneous adipose tissue. Several limitations of our study should also be acknowledged. The cross-sectional nature of this study does not allow us to determine neither a temporal nor a causal relationship between labor and alterations in adipose tissue region-specific gene expression. In addition, as most of the participants in the study were African-American, generalization of our findings to pregnant women with a different ethnic origin will require future investigation.

Conclusion

In conclusion, we have provided evidence for the association between labor and gene alterations in adipose tissue. Specifically, alternative splicing has been implicated in human parturition for the first time, providing a putative molecular mechanism by which regulation of adipose tissue metabolic adaptations to the increased energy demand associated with labor occurs. In addition, we have provided evidence that human parturition is characterized by a unique pattern of adipose tissue region-specific alterations in gene expression. Collectively, our data indicate that adipose tissue may play a role in metabolic regulation of human parturition.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported, in part, by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH); and, in part, with Federal funds from NICHD, NIH under Contract No. HSN275201300006C.

Reference List

1. Kashyap ML, Sivasamboo R, Sothy SP, Cheah JS, Gartside PS. Carbohydrate and lipid metabolism during human labor: free fatty acids, glucose, insulin, and lactic acid metabolism during normal and oxytocin-induced labor for postmaturity. *Metabolism*. 1976 Aug; 25(8):865–75. [PubMed: 940472]
2. Katz M, Kroll D, Shapiro Y, Cristal N, Meizner I. Energy expenditure in normal labor. *Isr J Med Sci*. 1990 May; 26(5):254–7. [PubMed: 2116380]
3. Whaley WH, Zuspan FP, Nelson GH, Ahlquist RP. Alterations of plasma free fatty acids and glucose during labor. *Am J Obstet Gynecol*. 1967 Apr; 97(7):1. 875–80. [PubMed: 4959599]
4. Raivio KO, Teramo K. Blood glucose of the human fetus prior to and during labor. *Acta Paediatr Scand*. 1968 Nov; 57(6):512–6. [PubMed: 5706366]

5. Paterson P, Phillips L, Wood C. Relationship between maternal and fetal blood glucose during labor. *Am J Obstet Gynecol.* 1967 Aug; 98(7):1. 938–45. [PubMed: 6067175]
6. Gurson CT, Etili L, Soyak S. Relation between endogenous lipoprotein lipase activity, free fatty acids, and glucose in plasma of women in labour and of their newborns. *Arch Dis Child.* 1968 Dec; 43(232):679–83. [PubMed: 5702227]
7. Felig P, Lynch V. Starvation in human pregnancy: hypoglycemia, hypoinsulinemia, and hyperketonemia. *Science.* 1970 Nov; 170(961):27. 990–2.
8. Low JA, Pancham SR, Worthington D, Boston RW. Acid-base, lactate, and pyruvate characteristics of the normal obstetric patient and fetus during the intrapartum period. *Am J Obstet Gynecol.* 1974 Dec; 120(7):1. 862–7. [PubMed: 4367310]
9. Banerjee B, Khew KS, Saha N, Ratnam SS. Energy cost and blood sugar level during different stages of labour and duration of labour in Asiatic women. *J Obstet Gynaecol Br Commonw.* 1971 Oct; 78(10):927–9. [PubMed: 5111900]
10. Milwidsky A, Gutman A. Glycogen metabolism of normal human myometrium and leiomyoma—possible hormonal control. *Gynecol Obstet Invest.* 1983; 15(3):147–52. [PubMed: 6403415]
11. Laudanski T. Energy metabolism of the myometrium in pregnancy and labor. *Zentralbl Gynakol.* 1985; 107(9):568–73. [PubMed: 4013554]
12. Mittal P, Romero R, Tarca AL, Gonzalez J, Draghici S, Xu Y, et al. Characterization of the myometrial transcriptome and biological pathways of spontaneous human labor at term. *J Perinat Med.* 2010 Nov; 38(6):617–43. [PubMed: 20629487]
13. Maheux PC, Bonin B, Dizazo A, Guimond P, Monier D, Bourque J, et al. Glucose homeostasis during spontaneous labor in normal human pregnancy. *J Clin Endocrinol Metab.* 1996 Jan; 81(1):209–15. [PubMed: 8550753]
14. Scheepers HC, de Jong PA, Essed GG, Kanhai HH. Fetal and maternal energy metabolism during labor in relation to the available caloric substrate. *J Perinat Med.* 2001; 29(6):457–64. [PubMed: 11776675]
15. Hotamisligil GS. Inflammation and metabolic disorders. *Nature.* 2006 Dec; 444(7121):14. 860–7. [PubMed: 17080050]
16. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. *Nature.* 2006 Dec; 444(7121):14. 847–53. [PubMed: 17080050]
17. Catalano PM, Hoegh M, Minium J, Huston-Presley L, Bernard S, Kalhan S, et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. *Diabetologia.* 2006 Jul; 49(7):1677–85. [PubMed: 16752186]
18. Mazaki-Tovi S, Kanety H, Sivan E. Adiponectin and human pregnancy. *Curr Diab Rep.* 2005 Aug; 5(4):278–81. [PubMed: 16033679]
19. Kajantie E, Hytinen T, Hovi P, Andersson S. Cord plasma adiponectin: a 20-fold rise between 24 weeks gestation and term. *J Clin Endocrinol Metab.* 2004 Aug; 89(8):4031–6. [PubMed: 15292345]
20. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Wiser A, Schiff E, et al. Maternal serum adiponectin levels during human pregnancy. *J Perinatol.* 2007 Feb; 27(2):77–81. [PubMed: 17262038]
21. Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, et al. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. *Clin Endocrinol (Oxf).* 2007 Mar; 66(3):447–53. [PubMed: 17302882]
22. Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Vaisbuch E, Gotsch F, et al. Adiponectin multimers in maternal plasma. *J Matern Fetal Neonatal Med.* 2008 Nov; 21(11):796–815. [PubMed: 19031276]
23. Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, et al. Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. *J Perinat Med.* 2007; 35(6):522–31. [PubMed: 17919116]
24. Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than NG, et al. Maternal visfatin concentration in normal pregnancy. *J Perinat Med.* 2009; 37(3):206–17. [PubMed: 19284295]
25. Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. *Endocrinology.* 2007 Nov; 148(11):5478–86. [PubMed: 17702846]

26. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Yissachar E, Schiff E, et al. Insulin sensitivity in late gestation and early postpartum period: the role of circulating maternal adipokines. *Gynecol Endocrinol*. 2011 Sep; 27(9):725–31. [PubMed: 21714696]
27. Nien JK, Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, et al. Resistin: a hormone which induces insulin resistance is increased in normal pregnancy. *J Perinat Med*. 2007; 35(6): 513–21. [PubMed: 17919114]
28. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Yissachar E, Schiff E, et al. Insulin sensitivity in late gestation and early postpartum period: the role of circulating maternal adipokines. *Gynecol Endocrinol*. 2011 Sep; 27(9):725–31. [PubMed: 21714696]
29. Kasher-Meron M, Mazaki-Tovi S, Barhod E, Hemi R, Haas J, Gat I, et al. Chemerin concentrations in maternal and fetal compartments: implications for metabolic adaptations to normal human pregnancy. *J Perinat Med*. 2014 May; 42(3):371–8. [PubMed: 24334424]
30. D'Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM. Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. *Obstet Gynecol*. 2005 Aug; 106(2):340–4. [PubMed: 16055585]
31. D'Anna R, Baviera G, Corrado F, Giordano D, De VA, Nicocia G, et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. *BJOG*. 2006 Nov; 113(11):1264–9. [PubMed: 17010118]
32. Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Gotsch F, et al. Maternal serum adiponectin multimers in preeclampsia. *J Perinat Med*. 2009; 37(4):349–63. [PubMed: 19348608]
33. Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. *Am J Physiol Endocrinol Metab*. 2006 Feb; 290(2):E326–E333. [PubMed: 16144822]
34. Kajantie E, Kaaja R, Ylikorkala O, Andersson S, Laivuori H. Adiponectin concentrations in maternal serum: elevated in preeclampsia but unrelated to insulin sensitivity. *J Soc Gynecol Investig*. 2005 Sep; 12(6):433–9.
35. Lu D, Yang X, Wu Y, Wang H, Huang H, Dong M. Serum adiponectin, leptin and soluble leptin receptor in pre-eclampsia. *Int J Gynaecol Obstet*. 2006 Aug.;17. [PubMed: 16756981]
36. Mazaki-Tovi S, Romero R, Kim SK, Vaisbuch E, Kusanovic JP, Erez O, et al. Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA? *J Matern Fetal Neonatal Med*. 2010 Aug; 23(8):857–68. [PubMed: 19900033]
37. Naruse K, Yamasaki M, Umekage H, Sado T, Sakamoto Y, Morikawa H. Peripheral blood concentrations of adiponectin, an adipocyte-specific plasma protein, in normal pregnancy and preeclampsia. *J Reprod Immunol*. 2005 Feb; 65(1):65–75. [PubMed: 15694968]
38. Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, et al. Adiponectin in severe preeclampsia. *J Perinat Med*. 2007; 35(6):503–12. [PubMed: 17919115]
39. Ramsay JE, Jamieson N, Greer IA, Sattar N. Paradoxical elevation in adiponectin concentrations in women with preeclampsia. *Hypertension*. 2003 Nov; 42(5):891–4. [PubMed: 14517227]
40. Vaisbuch E, Romero R, Mazaki-Tovi S, Erez O, Kim SK, Chaiworapongsa T, et al. Retinol binding protein 4—a novel association with early-onset preeclampsia. *J Perinat Med*. 2010 Mar; 38(2):129–39. [PubMed: 19708829]
41. Chen D, Dong M, Fang Q, He J, Wang Z, Yang X. Alterations of serum resistin in normal pregnancy and pre-eclampsia. *Clin Sci (Lond)*. 2005 Jan; 108(1):81–4. [PubMed: 15377276]
42. Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, et al. Circulating high-molecular-weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function. *Eur J Endocrinol*. 2008 Feb; 158(2):197–201. [PubMed: 18230826]
43. Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, et al. Serum levels of the adipokine visfatin are increased in pre-eclampsia. *Clin Endocrinol (Oxf)*. 2008 Jul; 69(1):69–73. [PubMed: 18034779]
44. Seol HJ, Kim JW, Kim HJ. Retinol-binding protein-4 is decreased in patients with preeclampsia in comparison with normal pregnant women. *J Perinat Med*. 2011 May; 39(3):287–9. [PubMed: 21299359]

45. Stepan H, Philipp A, Roth I, Kralisch S, Jank A, Schaarschmidt W, et al. Serum levels of the adipokine chemerin are increased in preeclampsia during and 6 months after pregnancy. *Regul Pept.* 2011 Jun 7; 168(1–3):69–72. [PubMed: 21477622]
46. Suwaki N, Masuyama H, Nakatsukasa H, Masumoto A, Sumida Y, Takamoto N, et al. Hypoadiponectinemia and circulating angiogenic factors in overweight patients complicated with pre-eclampsia. *Am J Obstet Gynecol.* 2006 Dec; 195(6):1687–92. [PubMed: 16769024]
47. Hendler I, Blackwell SC, Mehta SH, Whitty JE, Russell E, Sorokin Y, et al. The levels of leptin, adiponectin, and resistin in normal weight, overweight, and obese pregnant women with and without preeclampsia. *Am J Obstet Gynecol.* 2005 Sep; 193(3 Pt 2):979–83. [PubMed: 16157097]
48. Briana DD, Malamitsi-Puchner A. Adipocytokines in Normal and Complicated Pregnancies. *Reprod Sci.* 2009 May; 16(10):27. 921–37.
49. Fasshauer M, Bluher M, Stumvoll M, Tonessen P, Faber R, Stepan H. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. *Clin Endocrinol (Oxf).* 2007 Mar; 66(3):434–9. [PubMed: 17302880]
50. McCarthy JF, Misra DN, Roberts JM. Maternal plasma leptin is increased in preeclampsia and positively correlates with fetal cord concentration. *Am J Obstet Gynecol.* 1999 Mar; 180(3 Pt 1): 731–6. [PubMed: 10076155]
51. Schiff E, Friedman SA, Baumann P, Sibai BM, Romero R. Tumor necrosis factor-alpha in pregnancies associated with preeclampsia or small-for-gestational-age newborns. *Am J Obstet Gynecol.* 1994 May; 170(5 Pt 1):1224–9. [PubMed: 8178841]
52. Kinalski M, Telejko B, Kuzmicki M, Kretowski A, Kinalska I. Tumor necrosis factor alpha system and plasma adiponectin concentration in women with gestational diabetes. *Horm Metab Res.* 2005 Jul; 37(7):450–4. [PubMed: 16034719]
53. Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Mittal P, Chaiwaropongsa T, et al. Maternal Serum Adiponectin Multimers in Gestational Diabetes. *Journal Of Perinatal Medicine.* 2009; 37(6):637–50. [PubMed: 19530957]
54. Ranheim T, Haugen F, Staff AC, Braekke K, Harsem NK, Drevon CA. Adiponectin is reduced in gestational diabetes mellitus in normal weight women. *Acta Obstet Gynecol Scand.* 2004 Apr; 83(4):341–7. [PubMed: 15005780]
55. Worda C, Leipold H, Gruber C, Kautzky-Willer A, Knofler M, Bancher-Todesca D. Decreased plasma adiponectin concentrations in women with gestational diabetes mellitus. *Am J Obstet Gynecol.* 2004 Dec; 191(6):2120–4. [PubMed: 15592301]
56. Chan TF, Chen YL, Lee CH, Chou FH, Wu LC, Jong SB, et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. *J Soc Gynecol Investig.* 2006 Jul; 13(5):364–7.
57. Chan TF, Chen HS, Chen YC, Lee CH, Chou FH, Chen IJ, et al. Increased serum retinol-binding protein 4 concentrations in women with gestational diabetes mellitus. *Reprod Sci.* 2007 Feb; 14(2):169–74. [PubMed: 17636228]
58. Chen D, Fang Q, Chai Y, Wang H, Huang H, Dong M. Serum resistin in gestational diabetes mellitus and early postpartum. *Clin Endocrinol (Oxf).* 2007 Aug; 67(2):208–11. [PubMed: 17547683]
59. Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than NG, et al. Visfatin in human pregnancy: maternal gestational diabetes vis-a-vis neonatal birthweight. *J Perinat Med.* 2009 Jan. 37:1. 218–31. [PubMed: 19848450]
60. Haider DG, Handisurya A, Storka A, Vojtassakova E, Luger A, Pacini G, et al. Visfatin response to glucose is reduced in women with gestational diabetes mellitus. *Diabetes Care.* 2007 Jul; 30(7): 1889–91. [PubMed: 17416788]
61. Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. *Clin Sci (Lond).* 2006 May; 110(5):605–9. [PubMed: 16489932]
62. Krzyzanowska K, Zemany L, Krugluger W, Schernthaner GH, Mittermayer F, Schnack C, et al. Serum concentrations of retinol-binding protein 4 in women with and without gestational diabetes. *Diabetologia.* 2008 Jul; 51(7):1115–22. [PubMed: 18437353]

63. Kuzmicki M, Telejko B, Szamatowicz J, Zonenberg A, Nikolajuk A, Kretowski A, et al. High resistin and interleukin-6 levels are associated with gestational diabetes mellitus. *Gynecol Endocrinol*. 2009 Apr; 25(4):258–63. [PubMed: 19408175]
64. Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, Bienkiewicz M, et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. *Diabetologia*. 2007 May; 50(5):1033–7. [PubMed: 17334748]
65. Lewandowski KC, Stojanovic N, Bienkiewicz M, Tan BK, Prelevic GM, Press M, et al. Elevated concentrations of retinol-binding protein-4 (RBP-4) in gestational diabetes mellitus: negative correlation with soluble vascular cell adhesion molecule-1 (sVCAM-1). *Gynecol Endocrinol*. 2008 Jun; 24(6):300–5. [PubMed: 18584408]
66. Szamatowicz J, Kuzmicki M, Telejko B, Zonenberg A, Nikolajuk A, Kretowski A, et al. Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes. *Ginekol Pol*. 2009 Jan; 80(1):14–8. [PubMed: 19323054]
67. Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Mittal P, Chaiwaropongsa T, et al. Dysregulation of maternal serum adiponectin in preterm labor. *J Matern Fetal Neonatal Med*. 2009; 22:887–904. [PubMed: 19579094]
68. Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Chaiwaropongsa T, Mittal P, et al. Maternal Plasma Visfatin in Preterm Labor. *J Matern Fetal Neonatal Med*. 2009; 22:693–704. [PubMed: 19572235]
69. Mazaki-Tovi S, Romero R, Vaisbuch E, Kim SK, Kusanovic JP, Chaiwaropongsa T, et al. Evidence for differential regulation of the adipokine visfatin in the maternal and fetal compartments in normal spontaneous labor at term. *J Perinat Med*. 2010 May; 38(3):281–8. [PubMed: 20146661]
70. Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Chaiwaropongsa T, Kim SK, et al. Retinol-binding protein 4: a novel adipokine implicated in the genesis of LGA in the absence of gestational diabetes mellitus. *J Perinat Med*. 2010 Mar; 38(2):147–55. [PubMed: 20146659]
71. Briana DD, Boutsikou M, Baka S, Gourgiotis D, Marmarinos A, Hassiakos D, et al. Perinatal changes of plasma resistin concentrations in pregnancies with normal and restricted fetal growth. *Neonatology*. 2008; 93(3):153–7. [PubMed: 17878741]
72. Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Mittal P, Chaiwaropongsa T, et al. Maternal Serum Adiponectin Multimers in Patients with a Small-For-Gestational-Age Newborn. *J Perinat Med*. 2009; 37(6):623–35. [PubMed: 19530958]
73. Catov JM, Patrick TE, Powers RW, Ness RB, Harger G, Roberts JM. Maternal leptin across pregnancy in women with small-for-gestational-age infants. *Am J Obstet Gynecol*. 2007 Jun. 196(6):558. [PubMed: 17547894]
74. Mazaki-Tovi S, Vaisbuch E, Romero R, Kusanovic JP, Chaiwaropongsa T, Kim SK, et al. Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. *J Matern Fetal Neonatal Med*. 2010 Oct; 23(10):1119–28. [PubMed: 20121389]
75. Briana DD, Malamitsi-Puchner A. The role of adipocytokines in fetal growth. *Ann N Y Acad Sci*. 2010 Sep. 1205:82–7. [PubMed: 20840257]
76. Mazaki-Tovi S, Kasher-Meron M, Hemi R, Haas J, Gat I, Lantsberg D, et al. Chemerin is present in human cord blood and is positively correlated with birthweight. *Am J Obstet Gynecol*. 2012 Nov; 207(5):412–10. [PubMed: 22925375]
77. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Kuint J, Yinon Y, et al. Cord blood adiponectin and infant growth at one year. *J Pediatr Endocrinol Metab*. 2011; 24(7–8):411–8. [PubMed: 21932574]
78. Mazaki-Tovi S, Romero R, Vaisbuch E, Chaiwaropongsa T, Erez O, Mittal P, et al. Low circulating maternal adiponectin in patients with pyelonephritis: adiponectin at the crossroads of pregnancy and infection. *Journal Of Perinatal Medicine*. 2009; 38:9–17.
79. Mazaki-Tovi S, Vaisbuch E, Romero R, Kusanovic JP, Chaiwaropongsa T, Kim SK, et al. Maternal plasma concentration of the pro-inflammatory adipokine pre-B-cell-enhancing factor (PBEF)/visfatin is elevated in pregnant patients with acute pyelonephritis. *Am J Reprod Immunol*. 2010 Mar; 63(3):1. 252–62. [PubMed: 20565387]

80. Vaisbuch E, Romero R, Mazaki-Tovi S, Kusanovic JP, Chaiworapongsa T, Dong Z, et al. Maternal plasma retinol binding protein 4 in acute pyelonephritis during pregnancy. *J Perinat Med.* 2010 Jul; 38(4):359–66. [PubMed: 2016326]
81. Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Mittal P, et al. Adiponectin in amniotic fluid in normal pregnancy, spontaneous labor at term, and preterm labor: A novel association with subclinical intrauterine infection/inflammation. *J Matern Fetal Neonatal Med.* 2009; 23:120–30.
82. Vaisbuch E, Mazaki-Tovi S, Kusanovic JP, Erez O, Than GN, Kim SK, et al. Retinol Binding Protein 4: An Adipokine Associated with Intra-amniotic Infection/Inflammation. *J Matern Fetal Neonatal Med.* 2009
83. Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, Mittal P, et al. Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition. *J Perinat Med.* 2008; 36(6):485–96. [PubMed: 18598235]
84. Mazaki-Tovi S, Vaisbuch E, Romero R, Kusanovic JP, Chaiworapongsa T, Kim SK, et al. Hyperresistinemia - a novel feature in systemic infection during human pregnancy. *Am J Reprod Immunol.* 2010 May; 63(5):358–69. [PubMed: 20178460]
85. Karatas A, Ozlu T, Erdem A. Maternal metformin, obesity, and metabolic syndrome: the contribution of autonomic nervous system function. *Am J Obstet Gynecol.* 2014 Mar; 210(3):282.
86. Marrs CC, Moussa HN, Sibai BM, Blackwell SC. The relationship between primary cesarean delivery skin incision type and wound complications in women with morbid obesity. *Am J Obstet Gynecol.* 2014 Apr; 210(4):319–4. [PubMed: 24560557]
87. Subramaniam A, Jauk VC, Goss AR, Alvarez MD, Reese C, Edwards RK. Mode of delivery in women with class III obesity: planned cesarean compared with induction of labor. *Am J Obstet Gynecol.* 2014 Dec; 211(6):700–9. [PubMed: 24956550]
88. Mackeen AD, Schuster M, Berghella V. Suture versus staples for skin closure after cesarean: a metaanalysis. *Am J Obstet Gynecol.* 2015 May; 212(5):621. [PubMed: 25530592]
89. Mei-Dan E, Ray JG, Vigod SN. Perinatal outcomes among women with bipolar disorder: a population-based cohort study. *Am J Obstet Gynecol.* 2015 Mar; 212(3):367–8. [PubMed: 25446660]
90. Sugerman HJ. Effect of obesity on incidence of preeclampsia. *Am J Obstet Gynecol.* 2014 Apr; 210(4):375.
91. Zera CA, Seely EW, Wilkins-Haug LE, Lim KH, Parry SI, McElrath TF. The association of body mass index with serum angiogenic markers in normal and abnormal pregnancies. *Am J Obstet Gynecol.* 2014 Sep; 211(3):247. [PubMed: 24631439]
92. Kessous R, Shoham-Vardi I, Pariente G, Sergienko R, Holcberg G, Sheiner E. Recurrent pregnancy loss: a risk factor for long-term maternal atherosclerotic morbidity? *Am J Obstet Gynecol.* 2014 Oct; 211(4):414–11. [PubMed: 24905415]
93. Bigelow CA, Pereira GA, Warmley A, Cohen J, Getrajdman C, Moshier E, et al. Risk factors for new-onset late postpartum preeclampsia in women without a history of preeclampsia. *Am J Obstet Gynecol.* 2014 Apr; 210(4):338. [PubMed: 24211478]
94. Yao R, Ananth CV, Park BY, Pereira L, Plante LA. Obesity and the risk of stillbirth: a population-based cohort study. *Am J Obstet Gynecol.* 2014 May; 210(5):457–9. [PubMed: 24674712]
95. Harper LM, Jauk VC, Owen J, Biggio JR. The utility of ultrasound surveillance of fluid and growth in obese women. *Am J Obstet Gynecol.* 2014 Nov; 211(5):524–8. [PubMed: 24791732]
96. Lesseur C, Armstrong DA, Paquette AG, Li Z, Padbury JF, Marsit CJ. Maternal obesity and gestational diabetes are associated with placental leptin DNA methylation. *Am J Obstet Gynecol.* 2014 Dec; 211(6):654–9. [PubMed: 24954653]
97. Ahmadzia HK, Thomas SM, Dude AM, Grotegut CA, Boyd BK. Prediction of birthweight from third-trimester ultrasound in morbidly obese women. *Am J Obstet Gynecol.* 2014 Oct; 211(4):431–7. [PubMed: 24954654]
98. Hermann M, Le RC, Blondel B, Goffinet F, Zeitlin J. The risk of prelabor and intrapartum cesarean delivery among overweight and obese women: possible preventive actions. *Am J Obstet Gynecol.* 2015 Feb; 212(2):241–9. [PubMed: 25108139]

99. Acosta O, Ramirez VI, Lager S, Gaccioli F, Dudley DJ, Powell TL, et al. Increased glucose and placental GLUT-1 in large infants of obese nondiabetic mothers. *Am J Obstet Gynecol.* 2015 Feb; 212(2):227. [PubMed: 25132463]
100. Daly N, Stapleton M, O'Kelly R, Kinsley B, Daly S, Turner MJ. The role of preanalytical glycolysis in the diagnosis of gestational diabetes mellitus in obese women. *Am J Obstet Gynecol.* 2015 Mar.:12.
101. Poole AT, Vincent KL, Olson GL, Patrikeev I, Saade GR, Stuebe A, et al. Effect of lactation on maternal postpartum cardiac function and adiposity: a murine model. *Am J Obstet Gynecol.* 2014 Oct; 211(4):424–7. [PubMed: 24905416]
102. Sween LK, Althouse AD, Roberts JM. Early-pregnancy percent body fat in relation to preeclampsia risk in obese women. *Am J Obstet Gynecol.* 2015 Jan; 212(1):84–7. [PubMed: 25088867]
103. Ceyhan ST, Safer U, Cintosun U. Bioelectric impedance analysis in pregnant women. *Am J Obstet Gynecol.* 2015 Jan.212(1):120. [PubMed: 25281366]
104. Karachaliou M, Georgiou V, Roumeliotaki T, Chalkiadaki G, Daraki V, Koinaki S, et al. Association of trimester-specific gestational weight gain with fetal growth, offspring obesity, and cardiometabolic traits in early childhood. *Am J Obstet Gynecol.* 2015 Apr.212(4):502. [PubMed: 25557209]
105. Hancke K, Gundelach T, Hay B, Sander S, Reister F, Weiss JM. Pre-pregnancy obesity compromises obstetric and neonatal outcomes. *J Perinat Med.* 2015 Mar; 43(2):141–6. [PubMed: 24964255]
106. Farren M, Daly N, O'Higgins AC, McKeating A, Maguire PJ, Turner MJ. The interplay between maternal obesity and gestational diabetes mellitus. *J Perinat Med.* 2014 Nov.:11.
107. O'Higgins AC, Doolan A, Mullaney L, Daly N, McCartney D, Turner MJ. The relationship between gestational weight gain and fetal growth: time to take stock? *J Perinat Med.* 2014 Jul; 42(4):409–15. [PubMed: 24259236]
108. Kevane B, Donnelly J, D'Alton M, Cooley S, Preston RJ, Ni AF. Risk factors for pregnancy-associated venous thromboembolism: a review. *J Perinat Med.* 2014 Jul; 42(4):417–25. [PubMed: 24334422]
109. Zollner U, Dietl J. Perinatal risks after IVF and ICSI. *J Perinat Med.* 2013 Jan; 41(1):17–22. [PubMed: 23095186]
110. Gubler T, Krahenmann F, Roos M, Zimmermann R, Ochsenbein-Kolble N. Determinants of successful breastfeeding initiation in healthy term singletons: a Swiss university hospital observational study. *J Perinat Med.* 2013 May; 41(3):331–9. [PubMed: 23104852]
111. Willis K, Sheiner E. Bariatric surgery and pregnancy: the magical solution? *J Perinat Med.* 2013 Mar; 41(2):133–40. [PubMed: 23241580]
112. Galjaard S, Devlieger R, Van Assche FA. Fetal growth and developmental programming. *J Perinat Med.* 2013 Jan; 41(1):101–5. [PubMed: 23314514]
113. Horosz E, Bomba-Opon DA, Szymanska M, Wielgos M. Maternal weight gain in women with gestational diabetes mellitus. *J Perinat Med.* 2013 Sep; 41(5):1. 523–8.
114. Soni S, Chivan N, Cohen WR. Effect of maternal body mass index on oxytocin treatment for arrest of dilatation. *J Perinat Med.* 2013 Sep; 41(5):1. 517–21.
115. Tchernof A, Belanger C, Morisset AS, Richard C, Mailloux J, Laberge P, et al. Regional differences in adipose tissue metabolism in women: minor effect of obesity and body fat distribution. *Diabetes.* 2006 May; 55(5):1353–60. [PubMed: 16644692]
116. Dicker A, Astrom G, Wahlen K, Hoffstedt J, Naslund E, Wren M, et al. Primary differences in lipolysis between human omental and subcutaneous adipose tissue observed using in vitro differentiated adipocytes. *Horm Metab Res.* 2009 May; 41(5):350–5. [PubMed: 19204889]
117. Drolet R, Belanger C, Fortier M, Huot C, Mailloux J, Legare D, et al. Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. *Obesity (Silver Spring).* 2009 Mar; 17(3):424–30. [PubMed: 19219061]
118. Kuzmicki M, Telejko B, Wawrusiewicz-Kurylonek N, Kalejta K, Lemancewicz A, Zdrodowski M, et al. The expression of transcription factor 7-like 2 (TCF7L2) in fat and placental tissue from

- women with gestational diabetes. *Diabetes Res Clin Pract.* 2011 Nov; 94(2):e43–e46. [PubMed: 21855162]
119. Kuzmicki M, Telejko B, Wawrusiewicz-Kurylonek N, Nikolajuk A, Zwierz-Gugala D, Jelski W, et al. Retinol-binding protein 4 in adipose and placental tissue of women with gestational diabetes. *Gynecol Endocrinol.* 2011 Dec; 27(12):1065–9. [PubMed: 21609194]
 120. Ma Y, Cheng Y, Wang J, Cheng H, Zhou S, Li X. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. *Diabetes Res Clin Pract.* 2010 Oct; 90(1):60–5. [PubMed: 20621376]
 121. Lappas M, Mitton A, Permezel M. In response to oxidative stress, the expression of inflammatory cytokines and antioxidant enzymes are impaired in placenta, but not adipose tissue, of women with gestational diabetes. *J Endocrinol.* 2010 Jan; 204(1):75–84. [PubMed: 19833719]
 122. Kleiblova P, Dostalova I, Bartlova M, Lacinova Z, Ticha I, Krejci V, et al. Expression of adipokines and estrogen receptors in adipose tissue and placenta of patients with gestational diabetes mellitus. *Mol Cell Endocrinol.* 2010 Jan; 314(1):15. 150–6.
 123. Morgan SA, Bringolf JB, Seidel ER. Visfatin expression is elevated in normal human pregnancy. *Peptides.* 2008 Aug; 29(8):1382–9. [PubMed: 18524416]
 124. Barker G, Lim R, Georgiou HM, Lappas M. Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity. *PLoS One.* 2012; 7(8):e42943. [PubMed: 22952622]
 125. Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. *Obesity (Silver Spring).* 2010 May; 18(5):884–9. [PubMed: 20019678]
 126. Walker GE, Marzullo P, Verti B, Guzzaloni G, Maestrini S, Zurleni F, et al. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects. *Obesity (Silver Spring).* 2008 Sep; 16(9):1983–91. [PubMed: 19186324]
 127. Dolinkova M, Dostalova I, Lacinova Z, Michalsky D, Haluzikova D, Mraz M, et al. The endocrine profile of subcutaneous and visceral adipose tissue of obese patients. *Mol Cell Endocrinol.* 2008 Sep 10; 291(1–2):63–70. [PubMed: 18565643]
 128. Insenser M, Montes-Nieto R, Vilarrasa N, Lecube A, Simo R, Vendrell J, et al. A nontargeted proteomic approach to the study of visceral and subcutaneous adipose tissue in human obesity. *Mol Cell Endocrinol.* 2012 Nov 5; 363(1–2):10–9. [PubMed: 22796336]
 129. Avram MM, Avram AS, James WD. Subcutaneous fat in normal and diseased states 3. Adipogenesis: from stem cell to fat cell. *J Am Acad Dermatol.* 2007 Mar; 56(3):472–92. [PubMed: 17317490]
 130. Avram AS, Avram MM, James WD. Subcutaneous fat in normal and diseased states: 2. Anatomy and physiology of white and brown adipose tissue. *J Am Acad Dermatol.* 2005 Oct; 53(4):671–83. [PubMed: 16198791]
 131. Avram MM, Avram AS, James WD. Subcutaneous fat in normal and diseased states: 1. Introduction. *J Am Acad Dermatol.* 2005 Oct; 53(4):663–70. [PubMed: 16198790]
 132. Gealekman O, Guseva N, Hartigan C, Apotheker S, Gorgoglione M, Gurav K, et al. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. *Circulation.* 2011 Jan; 123(2):18. 186–94.
 133. Kloting N, Berthold S, Kovacs P, Schon MR, Fasshauer M, Ruschke K, et al. MicroRNA expression in human omental and subcutaneous adipose tissue. *PLoS One.* 2009; 4(3):e4699. [PubMed: 19259271]
 134. Linder K, Arner P, Flores-Morales A, Tollet-Egnell P, Norstedt G. Differentially expressed genes in visceral or subcutaneous adipose tissue of obese men and women. *J Lipid Res.* 2004 Jan; 45(1):148–54. [PubMed: 14563828]
 135. Mathur SK, Jain P, Mathur P. Microarray evidences the role of pathologic adipose tissue in insulin resistance and their clinical implications. *J Obes.* 2011; 2011:587495. [PubMed: 21603273]
 136. Mutch DM, Tordjman J, Pelloux V, Hanczar B, Henegar C, Poitou C, et al. Needle and surgical biopsy techniques differentially affect adipose tissue gene expression profiles. *Am J Clin Nutr.* 2009 Jan; 89(1):51–7. [PubMed: 19056587]

137. Vohl MC, Sladek R, Robitaille J, Gurd S, Marceau P, Richard D, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. *Obes Res.* 2004 Aug; 12(8):1217–22. [PubMed: 15340102]
138. Zha JM, Di WJ, Zhu T, Xie Y, Yu J, Liu J, et al. Comparison of gene transcription between subcutaneous and visceral adipose tissue in Chinese adults. *Endocr J.* 2009; 56(8):935–44. [PubMed: 19564704]
139. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. *Diabetes.* 2007 Jun; 56(6):1655–61. [PubMed: 17329619]
140. Van HV, Dicker A, Ryden M, Hauner H, Lonnqvist F, Naslund E, et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. *Diabetes.* 2002 Jul; 51(7):2029–36. [PubMed: 12086930]
141. Guan H, Arany E, van Beek JP, Chamson-Reig A, Thyssen S, Hill DJ, et al. Adipose tissue gene expression profiling reveals distinct molecular pathways that define visceral adiposity in offspring of maternal protein-restricted rats. *Am J Physiol Endocrinol Metab.* 2005 Apr; 288(4):E663–E673. [PubMed: 15562247]
142. Lee YS. The role of genes in the current obesity epidemic. *Ann Acad Med Singapore.* 2009 Jan; 38(1):45–3. [PubMed: 19221670]
143. Copland JA, Davies PJ, Shipley GL, Wood CG, Luxon BA, Urban RJ. The use of DNA microarrays to assess clinical samples: the transition from bedside to bench to bedside. *Recent Prog Horm Res.* 2003; 58:25–53. [PubMed: 12795413]
144. Einstein FH, Atzmon G, Yang XM, Ma XH, Rincon M, Rudin E, et al. Differential responses of visceral and subcutaneous fat depots to nutrients. *Diabetes.* 2005 Mar; 54(3):672–8. [PubMed: 15734842]
145. Einstein FH, Fishman S, Muzumdar RH, Yang XM, Atzmon G, Barzilai N. Accretion of visceral fat and hepatic insulin resistance in pregnant rats. *Am J Physiol Endocrinol Metab.* 2008 Feb; 294(2):E451–E455. [PubMed: 18073320]
146. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. *Nature.* 2006 Dec; 444(7121):14. 881–7. [PubMed: 17080050]
147. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. *Nature.* 2006 Dec; 444(7121):14. 875–80. [PubMed: 17080050]
148. Russell AW, McIntyre HD, Whitehead JP, Prins JB. Adipose tissue from pregnant women with and without gestational diabetes mellitus: insulin-sensitive but resistant to hyperosmolarity. *Am J Obstet Gynecol.* 2005 Dec; 193(6):2017–23. [PubMed: 16325606]
149. Wronska A, Kmiec Z. Structural and biochemical characteristics of various white adipose tissue depots. *Acta Physiol (Oxf).* 2012 Jun; 205(2):194–208. [PubMed: 22226221]
150. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. *Endocr Rev.* 2000 Dec; 21(6):697–738. [PubMed: 11133069]
151. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation.* 2007 Jul; 116(1):3. 39–48. [PubMed: 17606853]
152. von Eyben FE, Kroustrup JP, Larsen JF, Celis J. Comparison of gene expression in intra-abdominal and subcutaneous fat: a study of men with morbid obesity and nonobese men using microarray and proteomics. *Ann N Y Acad Sci.* 2004 Dec. 1030:508–36. [PubMed: 15659836]
153. Langin D, Holm C, Lafontan M. Adipocyte hormone-sensitive lipase: a major regulator of lipid metabolism. *Proc Nutr Soc.* 1996 Mar; 55(1B):93–109. [PubMed: 8832784]
154. Giusti V, Suter M, Verdumo C, Gaillard RC, Burckhardt P, Pralong FP. Molecular determinants of human adipose tissue: differences between visceral and subcutaneous compartments in obese women. *J Clin Endocrinol Metab.* 2004 Mar; 89(3):1379–84. [PubMed: 15001637]
155. Vidal H. Gene expression in visceral and subcutaneous adipose tissues. *Ann Med.* 2001 Nov; 33(8):547–55. [PubMed: 11730162]
156. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. *Mol Cell Endocrinol.* 2004 Apr 30; 219(1–2):9–15. [PubMed: 15149722]

157. Ryden M, Elizalde M, Van H V, Ohlund A, Hoffstedt J, Bringman S, et al. Increased expression of eNOS protein in omental versus subcutaneous adipose tissue in obese human subjects. *Int J Obes Relat Metab Disord*. 2001 Jun; 25(6):811–5. [PubMed: 11439294]
158. Livingston JN, Lerea KM, Bolinder J, Kager L, Backman L, Arner P. Binding and molecular weight properties of the insulin receptor from omental and subcutaneous adipocytes in human obesity. *Diabetologia*. 1984 Oct; 27(4):447–53. [PubMed: 6391988]
159. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. *Biochim Biophys Acta*. 2000 Jan; 1500(1):3. 88–96.
160. Marette A, Mauriege P, Marcotte B, Atgie C, Bouchard C, Theriault G, et al. Regional variation in adipose tissue insulin action and GLUT4 glucose transporter expression in severely obese premenopausal women. *Diabetologia*. 1997 May; 40(5):590–8. [PubMed: 9165229]
161. Atzmon G, Yang XM, Muzumdar R, Ma XH, Gabrieli I, Barzilai N. Differential gene expression between visceral and subcutaneous fat depots. *Horm Metab Res*. 2002 Nov; 34(11–12):622–8. [PubMed: 12660871]
162. Lefebvre AM, Laville M, Vega N, Riou JP, van G L, Auwerx J, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. *Diabetes*. 1998 Jan; 47(1):98–103. [PubMed: 9421381]
163. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. *Diabetes*. 1998 Sep; 47(9):1384–91. [PubMed: 9726225]
164. Lee MJ, Gong DW, Burkey BF, Fried SK. Pathways regulated by glucocorticoids in omental and subcutaneous human adipose tissues: a microarray study. *Am J Physiol Endocrinol Metab*. 2011 Mar; 300(3):E571–E580. [PubMed: 21189358]
165. VanH V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. *Diabetes*. 1998 Jun; 47(6):913–7. [PubMed: 9604868]
166. Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shigemoto M, et al. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue. *Diabetes*. 1995 Jul; 44(7):855–8. [PubMed: 7789654]
167. Hube F, Lietz U, Igel M, Jensen PB, Tornqvist H, Joost HG, et al. Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. *Horm Metab Res*. 1996 Dec; 28(12):690–3. [PubMed: 9013743]
168. Hojbjerre L, Alibegovic AC, Sonne MP, Dela F, Vaag A, Bruun JM, et al. Increased lipolysis but diminished gene expression of lipases in subcutaneous adipose tissue of healthy young males with intrauterine growth retardation. *J Appl Physiol*. 2011 Dec; 111(6):1863–70. [PubMed: 21903886]
169. Ma Y, Cheng Y, Wang J, Cheng H, Zhou S, Li X. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. *Diabetes Res Clin Pract*. 2010 Oct; 90(1):60–5. [PubMed: 20621376]
170. Liu Y, Zhu L, Pan Y, Sun L, Chen D, Li X. Adiponectin levels in circulation and breast milk and mRNA expression in adipose tissue of preeclampsia women. *Hypertens Pregnancy*. 2012; 31(1): 40–9. [PubMed: 21174574]
171. Telejko B, Kuzmicki M, Zonenberg A, Modzelewska A, Niedziolko-Bagniuk K, Ponurkiewicz A, et al. Ghrelin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. *Exp Clin Endocrinol Diabetes*. 2010 Feb; 118(2):87–92. [PubMed: 20180161]
172. Colomiere M, Permezel M, Lappas M. Diabetes and obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle and subcutaneous adipose tissue. *J Mol Endocrinol*. 2010 Apr; 44(4):213–23. [PubMed: 19955252]
173. Telejko B, Kuzmicki M, Wawrusiewicz-Kurylonek N, Szamatowicz J, Nikolajuk A, Zonenberg A, et al. Plasma apelin levels and apelin/APJ mRNA expression in patients with gestational diabetes mellitus. *Diabetes Res Clin Pract*. 2010 Feb; 87(2):176–83. [PubMed: 19926159]

174. Telejko B, Kuzmicki M, Zonenberg A, Szamatowicz J, Wawrusiewicz-Kurylonek N, Nikolajuk A, et al. Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. *Diabetes Res Clin Pract.* 2009 Apr; 84(1):68–75. [PubMed: 19185944]
175. Orcy RB, Schroeder S, Martins-Costa SH, Ramos JG, Schechinger W, Klein H, et al. Signalization of Akt/PKB in the placenta, skeletal muscle and adipose tissue of preeclampsia patients. *Gynecol Obstet Invest.* 2008; 66(4):231–6. [PubMed: 18645256]
176. Zhou Y, Zhang M, Guo W, Yu M, Xue K, Huang S, et al. Expression of resistin protein in normal human subcutaneous adipose tissue and pregnant women subcutaneous adipose tissue and placenta. *J Huazhong Univ Sci Technolog Med Sci.* 2006; 26(3):288–91. [PubMed: 16961271]
177. Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. *Am J Physiol Endocrinol Metab.* 2006 Feb; 290(2):E326–E333. [PubMed: 16144822]
178. Okuno S, Akazawa S, Yasuhi I, Kawasaki E, Matsumoto K, Yamasaki H, et al. Decreased expression of the GLUT4 glucose transporter protein in adipose tissue during pregnancy. *Horm Metab Res.* 1995 May; 27(5):231–4. [PubMed: 7642174]
179. Donker RB, Molema G, Faas MM, Kallenberg CG, van Pampus MG, Timmer A, et al. Absence of in vivo generalized pro-inflammatory endothelial activation in severe, early-onset preeclampsia. *J Soc Gynecol Investig.* 2005 Oct; 12(7):518–28.
180. Mackay VA, Huda SS, Stewart FM, Tham K, McKenna LA, Martin I, et al. Preeclampsia is associated with compromised maternal synthesis of long-chain polyunsaturated fatty acids, leading to offspring deficiency. *Hypertension.* 2012 Oct; 60(4):1078–85. [PubMed: 22949531]
181. Resi V, Basu S, Haghiac M, Presley L, Minium J, Kaufman B, et al. Molecular inflammation and adipose tissue matrix remodeling precede physiological adaptations to pregnancy. *Am J Physiol Endocrinol Metab.* 2012 Oct; 303(7):1. E832–E840.
182. Bemmo A, Benovoy D, Kwan T, Gaffney DJ, Jensen RV, Majewski J. Gene expression and isoform variation analysis using Affymetrix Exon Arrays. *BMC Genomics.* 2008; 9:529. [PubMed: 18990248]
183. Pacora P, Chaiworapongsa T, Maymon E, Kim YM, Gomez R, Yoon BH, et al. Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. *J Matern Fetal Med.* 2002 Jan; 11(1):18–25.
184. Redline RW. Inflammatory responses in the placenta and umbilical cord. *Semin Fetal Neonatal Med.* 2006 Oct; 11(5):296–301. [PubMed: 16621749]
185. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan MA. United States national reference for fetal growth. *Obstet Gynecol.* 1996 Feb; 87(2):163–8. [PubMed: 8559516]
186. Bashan N, Dorfman K, Tarnowski T, Harman-Boehm I, Liberty IF, Bluher M, et al. Mitogen-activated protein kinases, inhibitory-kappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. *Endocrinology.* 2007 Jun; 148(6):2955–62. [PubMed: 17317777]
187. Harman-Boehm I, Bluher M, Redel H, Sion-Vardy N, Ovadia S, Avinoach E, et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. *J Clin Endocrinol Metab.* 2007 Jun; 92(6):2240–7. [PubMed: 17374712]
188. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. *Diabetes.* 2005 Oct; 54(10):2911–6. [PubMed: 16186392]
189. Bluher M, Bashan N, Shai I, Harman-Boehm I, Tarnowski T, Avinoach E, et al. Activated Ask1-MKK4-p38MAPK/JNK stress signaling pathway in human omental fat tissue may link macrophage infiltration to whole-body Insulin sensitivity. *J Clin Endocrinol Metab.* 2009 Jul; 94(7):2507–15. [PubMed: 19351724]
190. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. *BMC Genomics.* 2006; 7:325. [PubMed: 17192196]

191. Kurokawa K, Kuwano Y, Tominaga K, Kawai T, Katsuura S, Yamagishi N, et al. Brief naturalistic stress induces an alternative splice variant of SMG-1 lacking exon 63 in peripheral leukocytes. *Neurosci Lett*. 2010 Oct; 484(2):29. 128–32.
192. Zhang W, Duan S, Bleibel WK, Wisel SA, Huang RS, Wu X, et al. Identification of common genetic variants that account for transcript isoform variation between human populations. *Hum Genet*. 2009 Feb; 125(1):81–93. [PubMed: 19052777]
193. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics*. 2003 Apr; 4(2):249–64. [PubMed: 12925520]
194. Bengtsson, H., S, K., B, J., H, K. aroma.affymetrix: A generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory. University of California; Berkeley: 2008 Feb 1. Tech Report # 745 of the Department of Statistics
195. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol*. 2004; 3 Article3.
196. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. *Behav Brain Res*. 2001 Nov 1; 125(1–2):279–84. [PubMed: 11682119]
197. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A*. 2001 Apr; 98(9):24. 5116–21.
198. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol*. 2004; 5(10):R80. [PubMed: 15461798]
199. Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, et al. A systems biology approach for pathway level analysis. *Genome Res*. 2007 Oct; 17(10):1537–45. [PubMed: 17785539]
200. Khatri P, Draghici S, Ostermeier GC, Krawetz SA. Profiling gene expression using onto-express. *Genomics*. 2002 Feb; 79(2):266–70. [PubMed: 11829497]
201. Tarca AL, Draghici S, Bhatti G, Romero R. Down-weighting overlapping genes improves gene set analysis. *BMC Bioinformatics*. 2012; 13:136. [PubMed: 22713124]
202. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*. 2005 Oct; 102(43):25. 15545–50.
203. Purdom E, Simpson KM, Robinson MD, Conboy JG, Lapuk AV, Speed TP. FIRMA: a method for detection of alternative splicing from exon array data. *Bioinformatics*. 2008 Aug; 24(15):1. 1707–14. [PubMed: 18024971]
204. Clark TA, Schweitzer AC, Chen TX, Staples MK, Lu G, Wang H, et al. Discovery of tissue-specific exons using comprehensive human exon microarrays. *Genome Biol*. 2007; 8(4):R64. [PubMed: 17456239]
205. Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, de B B, et al. Reactome: a knowledgebase of biological pathways. *Nucleic Acids Res*. 2005 Jan 1.33:D428–D432. (Database issue). [PubMed: 15608231]
206. Khoury MJ, Romero R. The integration of genomics into obstetrics and gynecology: a HuGE challenge. *Am J Obstet Gynecol*. 2006 Dec; 195(6):1503–5. [PubMed: 17132472]
207. Kolialexi A, Mavrou A, Spyrou G, Tsangaris GT. Mass spectrometry-based proteomics in reproductive medicine. *Mass Spectrom Rev*. 2008 Nov; 27(6):624–34. [PubMed: 18618655]
208. Romero R, Espinoza J, Gotsch F, Kusanovic JP, Friel LA, Erez O, et al. The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. *BJOG*. 2006 Dec; 113(Suppl 3):118–35. [PubMed: 17206980]
209. Romero R, Tromp G. High-dimensional biology in obstetrics and gynecology: functional genomics in microarray studies. *Am J Obstet Gynecol*. 2006 Aug; 195(2):360–3. [PubMed: 16890547]
210. Romero R, Kusanovic JP, Gotsch F, Erez O, Vaisbuch E, Mazaki-Tovi S, et al. Isobaric labeling and tandem mass spectrometry: A novel approach for profiling and quantifying proteins differentially expressed in amniotic fluid in preterm labor with and without intra-amniotic infection/inflammation. *J Matern Fetal Neonatal Med*. 2009 Aug.;6. [PubMed: 19718587]

211. Romero R, Mazaki-Tovi S, Vaisbuch E, Kusanovic JP, Chaiworapongsa T, Gomez R, et al. Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. *J Matern Fetal Neonatal Med.* 2010 Dec; 23(12):1344–59. [PubMed: 20504069]
212. Hassan SS, Romero R, Haddad R, Hendler I, Khalek N, Tromp G, et al. The transcriptome of the uterine cervix before and after spontaneous term parturition. *Am J Obstet Gynecol.* 2006 Sep; 195(3):778–86. [PubMed: 16949412]
213. Hassan SS, Romero R, Tarca AL, Draghici S, Pineles B, Bugrim A, et al. Signature pathways identified from gene expression profiles in the human uterine cervix before and after spontaneous term parturition. *Am J Obstet Gynecol.* 2007 Sep; 197(3):250–7. [PubMed: 17826407]
214. Hassan SS, Romero R, Tarca AL, Nhan-Chang CL, Vaisbuch E, Erez O, et al. The transcriptome of cervical ripening in human pregnancy before the onset of labor at term: identification of novel molecular functions involved in this process. *J Matern Fetal Neonatal Med.* 2009 Dec; 22(12):1183–93. [PubMed: 19883264]
215. Hassan SS, Romero R, Tarca AL, Nhan-Chang CL, Mittal P, Vaisbuch E, et al. The molecular basis for sonographic cervical shortening at term: identification of differentially expressed genes and the epithelial-mesenchymal transition as a function of cervical length. *Am J Obstet Gynecol.* 2010 Nov; 203(5):472. [PubMed: 20817141]
216. Hassan SS, Romero R, Pineles B, Tarca AL, Montenegro D, Erez O, et al. MicroRNA expression profiling of the human uterine cervix after term labor and delivery. *Am J Obstet Gynecol.* 2010 Jan; 202(1):80–8. [PubMed: 19889381]
217. Huber A, Hudelist G, Czerwenka K, Husslein P, Kubista E, Singer CF. Gene expression profiling of cervical tissue during physiological cervical effacement. *Obstet Gynecol.* 2005 Jan; 105(1):91–8. [PubMed: 15625148]
218. Mowa CN, Li T, Jesmin S, Folkesson HG, Usip SE, Papka RE, et al. Delineation of VEGF-regulated genes and functions in the cervix of pregnant rodents by DNA microarray analysis. *Reprod Biol Endocrinol.* 2008; 6:64. [PubMed: 19087268]
219. Read CP, Word RA, Ruscheinsky MA, Timmons BC, Mahendroo MS. Cervical remodeling during pregnancy and parturition: molecular characterization of the softening phase in mice. *Reproduction.* 2007 Aug; 134(2):327–40. [PubMed: 17660242]
220. Wang H, Stjernholm Y, Ekman G, Eriksson H, Sahlin L. Different regulation of oestrogen receptors alpha and beta in the human cervix at term pregnancy. *Mol Hum Reprod.* 2001 Mar; 7(3):293–300. [PubMed: 11228250]
221. Bethin KE, Nagai Y, Sladek R, Asada M, Sadovsky Y, Hudson TJ, et al. Microarray analysis of uterine gene expression in mouse and human pregnancy. *Mol Endocrinol.* 2003 Aug; 17(8):1454–69. [PubMed: 12775764]
222. Bukowski R, Hankins GD, Saade GR, Anderson GD, Thornton S. Labor-associated gene expression in the human uterine fundus, lower segment, and cervix. *PLoS Med.* 2006 Jun; 3(6):e169. [PubMed: 16768543]
223. Chan EC, Fraser S, Yin S, Yeo G, Kwek K, Fairclough RJ, et al. Human myometrial genes are differentially expressed in labor: a suppression subtractive hybridization study. *J Clin Endocrinol Metab.* 2002 Jun; 87(6):2435–41. [PubMed: 12050195]
224. Esplin MS, Fausett MB, Peltier MR, Hamblin S, Silver RM, Branch DW, et al. The use of cDNA microarray to identify differentially expressed labor-associated genes within the human myometrium during labor. *Am J Obstet Gynecol.* 2005 Aug; 193(2):404–13. [PubMed: 16098862]
225. Havelock JC, Keller P, Muleba N, Mayhew BA, Casey BM, Rainey WE, et al. Human myometrial gene expression before and during parturition. *Biol Reprod.* 2005 Mar; 72(3):707–19. [PubMed: 15509731]
226. O'Brien M, Morrison JJ, Smith TJ. Upregulation of PSCDBP, TLR2, TWIST1, FLJ35382, EDNRB, and RGS12 gene expression in human myometrium at labor. *Reprod Sci.* 2008 Apr; 15(4):382–93. [PubMed: 18497345]
227. Chaemsaihong P, Madan I, Romero R, Than NG, Tarca AL, Draghici S, et al. Characterization of the myometrial transcriptome in women with an arrest of dilatation during labor. *J Perinat Med.* 2013 Nov; 41(6):665–81. [PubMed: 23893668]

228. Haddad R, Tromp G, Kuivaniemi H, Chaiworapongsa T, Kim YM, Mazor M, et al. Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature. *Am J Obstet Gynecol.* 2006
229. Nhan-Chang CL, Romero R, Tarca AL, Mittal P, Kusanovic JP, Erez O, et al. Characterization of the transcriptome of chorioamniotic membranes at the site of rupture in spontaneous labor at term. *Am J Obstet Gynecol.* 2010 May; 202(5):462–41. [PubMed: 20452490]
230. Bujold E, Romero R, Kusanovic JP, Erez O, Gotsch F, Chaiworapongsa T, et al. Proteomic profiling of amniotic fluid in preterm labor using two-dimensional liquid separation and mass spectrometry. *J Matern Fetal Neonatal Med.* 2008 Oct; 21(10):697–713. [PubMed: 19012186]
231. Cho CK, Shan SJ, Winsor EJ, Diamandis EP. Proteomics analysis of human amniotic fluid. *Mol Cell Proteomics.* 2007 Aug; 6(8):1406–15. [PubMed: 17495049]
232. Cobo T, Palacio M, Navarro-Sastre A, Ribes A, Bosch J, Filella X, et al. Predictive value of combined amniotic fluid proteomic biomarkers and interleukin-6 in preterm labor with intact membranes. *Am J Obstet Gynecol.* 2009 May; 200(5):499–6. [PubMed: 19375569]
233. Gravett MG, Novy MJ, Rosenfeld RG, Reddy AP, Jacob T, Turner M, et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. *JAMA.* 2004 Jul; 292(4):28. 462–9. [PubMed: 15238574]
234. Michaels JE, Dasari S, Pereira L, Reddy AP, Lapidus JA, Lu X, et al. Comprehensive proteomic analysis of the human amniotic fluid proteome: gestational age-dependent changes. *J Proteome Res.* 2007 Apr; 6(4):1277–85. [PubMed: 17373841]
235. Park JS, Oh KJ, Norwitz ER, Han JS, Choi HJ, Seong HS, et al. Identification of proteomic biomarkers of preeclampsia in amniotic fluid using SELDI-TOF mass spectrometry. *Reprod Sci.* 2008 May; 15(5):457–68. [PubMed: 18579854]
236. Park SJ, Yoon WG, Song JS, Jung HS, Kim CJ, Oh SY, et al. Proteome analysis of human amnion and amniotic fluid by two-dimensional electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Proteomics.* 2006 Jan; 6(1):349–63. [PubMed: 16294308]
237. Romero R, Espinoza J, Rogers WT, Moser A, Nien JK, Kusanovic JP, et al. Proteomic analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: the use of a novel computational method to analyze mass spectrometric profiling. *J Matern Fetal Neonatal Med.* 2008 Jun; 21(6):367–88. [PubMed: 18570116]
238. Ruetschi U, Rosen A, Karlsson G, Zetterberg H, Rymo L, Hagberg H, et al. Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. *J Proteome Res.* 2005 Nov; 4(6):2236–42. [PubMed: 16335971]
239. Vuadens F, Benay C, Crettaz D, Gallot D, Sapin V, Schneider P, et al. Identification of biologic markers of the premature rupture of fetal membranes: proteomic approach. *Proteomics.* 2003 Aug; 3(8):1521–5. [PubMed: 12923777]
240. Madan I, Than NG, Romero R, Chaemsaihong P, Miranda J, Tarca AL, et al. The peripheral whole-blood transcriptome of acute pyelonephritis in human pregnancy. *J Perinat Med.* 2014 Jan; 42(1):31–53. [PubMed: 24293448]
241. Madsen-Bouterse SA, Romero R, Tarca AL, Kusanovic JP, Espinoza J, Kim CJ, et al. The transcriptome of the fetal inflammatory response syndrome. *Am J Reprod Immunol.* 2010 Jan; 63(1):73–92. [PubMed: 20059468]
242. Alvehus M, Buren J, Sjöström M, Goedecke J, Olsson T. The human visceral fat depot has a unique inflammatory profile. *Obesity (Silver Spring).* 2010 May; 18(5):879–83. [PubMed: 20186138]
243. Miranda M, Escote X, Ceperuelo-Mallafre V, Alcaide MJ, Simon I, Vilarrasa N, et al. Paired subcutaneous and visceral adipose tissue aquaporin-7 expression in human obesity and type 2 diabetes: differences and similarities between depots. *J Clin Endocrinol Metab.* 2010 Jul; 95(7):3470–9. [PubMed: 20463097]
244. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. *Obes Rev.* 2010 Jan; 11(1):11–8. [PubMed: 19656312]

245. varez-Llamas G, Szalowska E, de Vries MP, Weening D, Landman K, Hoek A, et al. Characterization of the human visceral adipose tissue secretome. *Mol Cell Proteomics*. 2007 Apr; 6(4):589–600. [PubMed: 17255083]
246. Okuno S, Akazawa S, Yasuhi I, Kawasaki E, Matsumoto K, Yamasaki H, et al. Decreased expression of the GLUT4 glucose transporter protein in adipose tissue during pregnancy. *Horm Metab Res*. 1995 May; 27(5):231–4. [PubMed: 7642174]
247. Donker RB, Molema G, Faas MM, Kallenberg CG, van Pampus MG, Timmer A, et al. Absence of in vivo generalized pro-inflammatory endothelial activation in severe, early-onset preeclampsia. *J Soc Gynecol Investig*. 2005 Oct; 12(7):518–28.
248. Bashiri A, Heo HJ, Ben-Avraham D, Mazor M, Budagov T, Einstein FH, et al. Pregnancy complicated by obesity induces global transcript expression alterations in visceral and subcutaneous fat. *Mol Genet Genomics*. 2014 Aug; 289(4):695–705. [PubMed: 24696292]
249. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. *Mol Cell Proteomics*. 2008 Jul; 7(7):1214–24. [PubMed: 18353764]
250. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. *Science*. 2003 Dec; 302(5653):19. 2141–4.
251. Kampa D, Cheng J, Kapranov P, Yamanaka M, Brubaker S, Cawley S, et al. Novel RNAs identified from an in-depth analysis of the transcriptome of human chromosomes 21 and 22. *Genome Res*. 2004 Mar; 14(3):331–42. [PubMed: 14993201]
252. Moller-Levet CS, Betts GN, Harris AL, Homer JJ, West CM, Miller CJ. Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis. *PLoS Comput Biol*. 2009 Nov.5(11):e1000571. [PubMed: 19936049]
253. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, et al. Function of alternative splicing. *Gene*. 2005 Jan.344:3. 1–20.
254. Lareau LF, Inada M, Green RE, Wengrod JC, Brenner SE. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. *Nature*. 2007 Apr; 446(7138):19. 926–9.
255. Ni JZ, Grate L, Donohue JP, Preston C, Nobida N, O'Brien G, et al. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. *Genes Dev*. 2007 Mar; 21(6):15. 708–18.
256. Venables JP. Unbalanced alternative splicing and its significance in cancer. *Bioessays*. 2006 Apr; 28(4):378–86. [PubMed: 16547952]
257. Harris JM, Meyer DJ, Coles B, Ketterer B. A novel glutathione transferase (13-13) isolated from the matrix of rat liver mitochondria having structural similarity to class theta enzymes. *Biochem J*. 1991 Aug 15; 278(Pt 1):137–41. [PubMed: 1883325]
258. Morel F, Rauch C, Petit E, Piton A, Theret N, Coles B, et al. Gene and protein characterization of the human glutathione S-transferase kappa and evidence for a peroxisomal localization. *J Biol Chem*. 2004 Apr; 279(16):16. 16246–53.
259. Morel F, Rauch C, Petit E, Piton A, Theret N, Coles B, et al. Gene and protein characterization of the human glutathione S-transferase kappa and evidence for a peroxisomal localization. *J Biol Chem*. 2004 Apr; 279(16):16. 16246–53.
260. Thomson RE, Bigley AL, Foster JR, Jowsey IR, Elcombe CR, Orton TC, et al. Tissue-specific expression and subcellular distribution of murine glutathione S-transferase class kappa. *J Histochem Cytochem*. 2004 May; 52(5):653–62. [PubMed: 15100242]
261. Jowsey IR, Thomson RE, Orton TC, Elcombe CR, Hayes JD. Biochemical and genetic characterization of a murine class Kappa glutathione S-transferase. *Biochem J*. 2003 Jul 15; 373(Pt 2):559–69. [PubMed: 12720545]
262. Shield AJ, Murray TP, Cappello JY, Coggan M, Board PG. Polymorphisms in the human glutathione transferase Kappa (GSTK1) promoter alter gene expression. *Genomics*. 2010 May; 95(5):299–305. [PubMed: 20193754]
263. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J Biol Chem*. 1996 May; 271(18):3. 10697–703.

264. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). *Biochem Biophys Res Commun.* 1996 Apr; 221(2):16. 286–9.
265. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. *J Biochem (Tokyo).* 1996 Oct; 120(4):803–12. [PubMed: 8947845]
266. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J Biol Chem.* 1995 Nov; 270(45):10. 26746–9.
267. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. *Blood.* 2000 Sep; 96(5):1. 1723–32. [PubMed: 10891424]
268. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. *Nat Med.* 2001 Aug; 7(8):947–53. [PubMed: 11479628]
269. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. *Horm Metab Res.* 2000 Feb; 32(2):47–50. [PubMed: 10741683]
270. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. *Hypertension.* 2004 Jun; 43(6):1318–23. [PubMed: 15123570]
271. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. *J Clin Endocrinol Metab.* 2002 Jun; 87(6):2764–9. [PubMed: 12050247]
272. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. *J Biol Chem.* 2004 Jan; 279(2):9. 1304–9.
273. McLachlan KA, O'Neal D, Jenkins A, Alford FP. Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. *Diabetes Metab Res Rev.* 2006 Mar; 22(2):131–8. [PubMed: 16170833]
274. Ategbro JM, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. *J Clin Endocrinol Metab.* 2006 Oct; 91(10):4137–43. [PubMed: 16849405]
275. Thyfault JP, Hedberg EM, Anchan RM, Thorne OP, Isler CM, Newton ER, et al. Gestational diabetes is associated with depressed adiponectin levels. *J Soc Gynecol Investig.* 2005 Jan; 12(1): 41–5.
276. Suwaki N, Masuyama H, Nakatsukasa H, Masumoto A, Sumida Y, Takamoto N, et al. Hypoadiponectinemia and circulating angiogenic factors in overweight patients complicated with pre-eclampsia. *Am J Obstet Gynecol.* 2006 Jun.;12.
277. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. *J Biol Chem.* 2004 Mar; 279(13):26. 12152–62. [PubMed: 14551184]
278. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. *J Biol Chem.* 2003 Oct; 278(41):10. 40352–63.
279. Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. *J Biol Chem.* 2003 Dec; 278(50):12. 50810–7.
280. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature.* 2003 Jun; 423(6941):12. 762–9.
281. Araki S, Dobashi K, Kubo K, Asayama K, Shirahata A. High molecular weight, rather than total, adiponectin levels better reflect metabolic abnormalities associated with childhood obesity. *J Clin Endocrinol Metab.* 2006 Dec; 91(12):5113–6. [PubMed: 16984991]

282. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. *Circ Res.* 2004 Mar 5; 94(4):e27–e31. [PubMed: 14752031]
283. Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. *Fertil Steril.* 2007 Aug.;11.
284. Modan-Moses D, Stein D, Pariente C, Yaroslavsky A, Ram A, Faigin M, et al. Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. *J Clin Endocrinol Metab.* 2007 May; 92(5):1843–7. [PubMed: 17327386]
285. Ong GK, Hamilton JK, Sermer M, Connelly PW, Maguire G, Zinman B, et al. Maternal serum adiponectin and infant birthweight: the role of adiponectin isoform distribution. *Clin Endocrinol (Oxf).* 2007 Jul; 67(1):108–14. [PubMed: 17466005]
286. Retnakaran R, Hanley AJ, Connelly PW, Maguire G, Sermer M, Zinman B. Low serum levels of high-molecular weight adiponectin in Indo-Asian women during pregnancy: evidence of ethnic variation in adiponectin isoform distribution. *Diabetes Care.* 2006 Jun; 29(6):1377–9. [PubMed: 16732024]
287. Takemura Y, Osuga Y, Koga K, Tajima T, Hirota Y, Hirata T, et al. Selective increase in high molecular weight adiponectin concentration in serum of women with preeclampsia. *J Reprod Immunol.* 2007 Feb; 73(1):60–5. [PubMed: 16860876]
288. Retnakaran R, Connelly PW, Maguire G, Sermer M, Zinman B, Hanley AJ. Decreased high-molecular-weight adiponectin in gestational diabetes: implications for the pathophysiology of Type 2 diabetes. *Diabet Med.* 2007 Mar; 24(3):245–52. [PubMed: 17305786]
289. Qian Y, Zheng Y, Taylor R, Tiffany-Castiglioni E. Involvement of the molecular chaperone Hspa5 in copper homeostasis in astrocytes. *Brain Res.* 2012 Apr.1447:4. 9–19.
290. Qian Y, Meng B, Zhang X, Zheng Y, Taylor R, Tiffany-Castiglioni E. HSPA5 Forms Specific Complexes with Copper. *Neurochem Res.* 2012 Nov.;17.
291. Uckun FM, Qazi S, Ozer Z, Garner AL, Pitt J, Ma H, et al. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. *Br J Haematol.* 2011 Jun; 153(6):741–52. [PubMed: 21517817]
292. Wisniewska M, Karlberg T, Lehtio L, Johansson I, Kotenyova T, Moche M, et al. Crystal structures of the ATPase domains of four human Hsp70 isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B', and HSPA5/BiP/GRP78. *PLoS One.* 2010; 5(1):e8625. [PubMed: 20072699]
293. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell.* 2010 Mar; 140(6):19. 900–17. [PubMed: 20085699]
294. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. *Nat Rev Immunol.* 2008 Sep; 8(9):663–74. [PubMed: 18670423]
295. Pfaffenbach KT, Lee AS. The critical role of GRP78 in physiologic and pathologic stress. *Curr Opin Cell Biol.* 2011 Apr; 23(2):150–6. [PubMed: 20970977]
296. Sharma NK, Das SK, Mondal AK, Hackney OG, Chu WS, Kern PA, et al. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. *J Clin Endocrinol Metab.* 2008 Nov; 93(11):4532–41. [PubMed: 18728164]
297. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science.* 2004 Oct; 306(5695):15. 457–61.
298. Nakatani Y, Kaneto H, Kawamori D, Yoshiuchi K, Hatazaki M, Matsuoka TA, et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. *J Biol Chem.* 2005 Jan; 280(1):7. 847–51.
299. Das SK, Chu WS, Mondal AK, Sharma NK, Kern PA, Rasouli N, et al. Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines. *Am J Physiol Endocrinol Metab.* 2008 Aug; 295(2):E393–E400. [PubMed: 18544642]

300. Mondal AK, Das SK, Varma V, Nolen GT, McGehee RE, Elbein SC, et al. Effect of endoplasmic reticulum stress on inflammation and adiponectin regulation in human adipocytes. *Metab Syndr Relat Disord*. 2012 Aug; 10(4):297–306. [PubMed: 22545589]
301. Li A, Ponten F, dos Remedios CG. The interactome of LIM domain proteins: the contributions of LIM domain proteins to heart failure and heart development. *Proteomics*. 2012 Jan; 12(2):203–25. [PubMed: 22253135]
302. Kovalevich J, Tracy B, Langford D. PINCH: More than just an adaptor protein in cellular response. *J Cell Physiol*. 2011 Apr; 226(4):940–7. [PubMed: 20945343]
303. Wu C. PINCH, N(i)ck and the ILK: network wiring at cell-matrix adhesions. *Trends Cell Biol*. 2005 Sep; 15(9):460–6. [PubMed: 16084094]
304. Chen H, Huang XN, Yan W, Chen K, Guo L, Tummalapali L, et al. Role of the integrin-linked kinase/PINCH1/alpha-parvin complex in cardiac myocyte hypertrophy. *Lab Invest*. 2005 Nov; 85(11):1342–56. [PubMed: 16170337]
305. Hannigan GE, Coles JG, Dedhar S. Integrin-linked kinase at the heart of cardiac contractility, repair, and disease. *Circ Res*. 2007 May; 100(10):25. 1408–14.
306. Liang X, Zhou Q, Li X, Sun Y, Lu M, Dalton N, et al. PINCH1 plays an essential role in early murine embryonic development but is dispensable in ventricular cardiomyocytes. *Mol Cell Biol*. 2005 Apr; 25(8):3056–62. [PubMed: 15798193]
307. Liang X, Sun Y, Schneider J, Ding JH, Cheng H, Ye M, et al. Pinch1 is required for normal development of cranial and cardiac neural crest-derived structures. *Circ Res*. 2007 Mar; 100(4):2. 527–35.
308. Liang X, Sun Y, Ye M, Scimia MC, Cheng H, Martin J, et al. Targeted ablation of PINCH1 and PINCH2 from murine myocardium results in dilated cardiomyopathy and early postnatal lethality. *Circulation*. 2009 Aug; 120(7):18. 568–76.
309. Liang X, Sun Y, Chen J. Particularly interesting cysteine- and histidine-rich protein in cardiac development and remodeling. *J Invest Med*. 2009 Dec; 57(8):842–8.
310. Jung KY, Chen K, Kretzler M, Wu C. TGF-beta1 regulates the PINCH-1-integrin-linked kinase-alpha-parvin complex in glomerular cells. *J Am Soc Nephrol*. 2007 Jan; 18(1):66–73. [PubMed: 17167118]
311. Shi X, Qu H, Kretzler M, Wu C. Roles of PINCH-2 in regulation of glomerular cell shape change and fibronectin matrix deposition. *Am J Physiol Renal Physiol*. 2008 Jul; 295(1):F253–F263. [PubMed: 18480182]
312. Yang Y, Guo L, Blattner SM, Mundel P, Kretzler M, Wu C. Formation and phosphorylation of the PINCH-1-integrin linked kinase-alpha-parvin complex are important for regulation of renal glomerular podocyte adhesion, architecture, and survival. *J Am Soc Nephrol*. 2005 Jul; 16(7):1966–76. [PubMed: 15872073]
313. Gkretsi V, Mars WM, Bowen WC, Barua L, Yang Y, Guo L, et al. Loss of integrin linked kinase from mouse hepatocytes in vitro and in vivo results in apoptosis and hepatitis. *Hepatology*. 2007 Apr; 45(4):1025–34. [PubMed: 17385211]
314. Tu Y, Li F, Goicoechea S, Wu C. The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. *Mol Cell Biol*. 1999 Mar; 19(3):2425–34. [PubMed: 10022929]
315. Wang-Rodriguez J, Dreilinger AD, Alsharabi GM, Rearden A. The signaling adapter protein PINCH is up-regulated in the stroma of common cancers, notably at invasive edges. *Cancer*. 2002 Sep; 95(6):15. 1387–95. [PubMed: 12115311]
316. Zhang JT, Li QX, Wang D, Zhu ZL, Yang YH, Cui DS, et al. Up-regulation of PINCH in the stroma of oral squamous cell carcinoma predicts nodal metastasis. *Oncol Rep*. 2005 Dec; 14(6):1519–22. [PubMed: 16273248]
317. Zhu Z, Yang Y, Zhang Y, Wang Z, Cui D, Zhang J, et al. PINCH expression and its significance in esophageal squamous cell carcinoma. *Dis Markers*. 2008; 25(2):75–80. [PubMed: 18957717]
318. Kim SK, Jang HR, Kim JH, Noh SM, Song KS, Kim MR, et al. The epigenetic silencing of LIMS2 in gastric cancer and its inhibitory effect on cell migration. *Biochem Biophys Res Commun*. 2006 Oct; 349(3):27. 1032–40.

319. Wang MW, Gu P, Zhang ZY, Zhu ZL, Li YM, Zhao HX, et al. Expression of PINCH protein in gliomas and its clinicopathological significance. *Oncology*. 2007; 72(5–6):343–6. [PubMed: 18187956]
320. Hehlhans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. *Biochim Biophys Acta*. 2007 Jan; 1775(1):163–80. [PubMed: 17084981]
321. Chen K, Tu Y, Zhang Y, Blair HC, Zhang L, Wu C. PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells. *J Biol Chem*. 2008 Feb; 283(5):1. 2508–17. [PubMed: 17999957]

Figure 1.

Differential expression of visceral versus subcutaneous adipose tissue transcripts in pregnant women in labor. Volcano plot showing differential expression evidence between subcutaneous and visceral adipose tissue of women in labor. The x-axis represents the log₂ fold changes in expression with positive values representing over-expression in the subcutaneous region compared to visceral. Transcripts outside the vertical red bars have fold change > 1.5. The y-axis represents the q-values ($-\log_{10}$ of), with values above 1.0 corresponding to $q < 0.1$.

Figure 2.

Heat map representing fat depot-specific differences in gene expression of pregnant women in labor. Heatmap showing the consistency of gene expression levels between subcutaneous and visceral regions of the adipose tissue of women in labor. Log_2 transformed transcript expression values are centered and scaled row-wise.

Figure 3.

Pathway perturbation associated with parturition in subcutaneous tissue. PADOG pathway enrichment plots showing evidence of pathway perturbation associated with parturition in subcutaneous tissue. The distribution of moderated t-scores of genes in KEGG spliceosome and reactome mRNA splicing is superimposed on the distribution of all genes on the array, and shows more differential expression in these pathways than in the pool of all genes.

Figure 4.

Differential exon usage for *LIMS1* gene in subcutaneous adipose tissue of women with and without labor. The top panel shows the log₂ expression of probes targeting 12 exonic regions of the *LIMS1* gene (separated by vertical gray lines). There are 1–4 probes per probeset. Each line corresponds to a sample, with colors blue and gray denoting one patient with and without labor, respectively. The second exon from the 5' end targeted by Affymetrix probeset ID 2499062 (see red rectangles), shows systematically lower expression in women in labor, while the expression level for all other exons is very similar between groups, hence resulting in significantly lower FIRMA scores for this probeset between groups. The middle panel shows the genomic region and the gene model with each exon represented by one olive-colored rectangle. ENSEMBL transcripts that do or do not include the exon with differential usage are represented in blue with their corresponding identifiers.

Figure 5.

Differential exon usage for the GSTK1 gene in subcutaneous adipose tissue of women with and without labor. See Figure 3 legend for layout details. Affymetrix probeset ID 3028993 (see red rectangles), shows systematically lower expression in women in labor, while the expression level for all other exons is very similar between groups, hence resulting in significantly lower FIRMA scores for this probeset between groups. The only ENSEMBL transcript that includes the exonic region with differential usage between groups is ENST00000479303, and an imbalance of this isoform with respect to the other isoforms can explain the observed differences.

Table 1

Demographic and clinical characteristics

	Term Labor N = 15	Term Not in Labor N = 25	p
Maternal age (years)	26 (24–38)	27 (25–39)	0.2
Gestational age at delivery (weeks)	39.7 (39–40.6)	39.1 (38.9–39.4)	0.2
Pre-gestational BMI (kg/m²)	35.3 (30.9–38.5)	37.5 (26.2–40.2)	0.5
BMI at Sampling (kg/m²)	36.9 (32.5–39.7)	37.2 (27.8–45.4)	0.8
Gravidity	3 (2–3)	3 (2–4)	0.5
Parity	2 (1–3)	2 (2–3)	0.2
Ethnic Origin (%)			1.0
African American	91.7	83.3	
Caucasian	8.3	16.7	
Systolic Blood Pressure (mmHg)	124 (117–127)	121 (115–126)	0.4
Diastolic Blood Pressure (mmHg)	75 (67–79)	66 (62–77)	0.3
Cervical Dilatation at Sampling	5 (4–7)	1 (1–2)	<0.001
Fasting Glucose (mg/dl)	93 (87–98)	94 (88–97)	0.7
Birth Weight (grams)	3320 (3155–3825)	3275 (3105–3500)	0.7

Data are presented as median and interquartile range (IQR). BMI - Body Mass Index

Table 2

A list of the top 100 differentially expressed genes between visceral and subcutaneous adipose tissue of patients with and without spontaneous labor at term

ENTREZ	SYMBOL	Name	Fold Change	q-value
364	AQP7	aquaporin 7	1.6	0.007
355	FAS	Fas (TNF receptor superfamily, member 6)	-1.9	0.007
100293763	AQP7P1	aquaporin 7 pseudogene 1	1.8	0.007
9871*	SEC24D	SEC24 family, member D (S. cerevisiae)	-1.7	0.007
83666*	PARP9	poly (ADP-ribose) polymerase family, member 9	-1.6	0.008
729085*	CCBP2	chemokine binding protein 2	-1.6	0.008
6285	S100B	S100 calcium binding protein B	1.6	0.008
10555	AGPAT2	1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta)	1.6	0.008
6574	SLC20A1	solute carrier family 20 (phosphate transporter), member 1	-1.9	0.008
54566	EPB41L4B	erythrocyte membrane protein band 4.1 like 4B	1.6	0.008
58477*	SRPRB	signal recognition particle receptor, B subunit	-1.8	0.008
54988*	ACSM5	acyl-CoA synthetase medium-chain family member 5	1.6	0.008
9180	OSMR	oncostatin M receptor	-1.9	0.008
284221	FAM38B2	family with sequence similarity 38, member B2	-2.0	0.008
2819	GPD1	glycerol-3-phosphate dehydrogenase 1 (soluble)	1.7	0.008
9052	GPRC5A	G protein-coupled receptor, family C, group 5, member A	-1.7	0.008
10973*	ASCC3	activating signal cointegrator 1 complex subunit 3	-1.5	0.008
6517	SLC2A4	solute carrier family 2 (facilitated glucose transporter), member 4	1.6	0.008
6713	SQLE	squalene epoxidase	-1.6	0.008
83716	CRISPLD2	cysteine-rich secretory protein LCCL domain containing 2	-1.9	0.008
10249	GLYAT	glycine-N-acyltransferase	2.4	0.008
23555	TSPAN15	tetraspanin 15	1.6	0.008
8908	GYG2	glycogenin 2	1.5	0.008
5578	PRKCA	protein kinase C, alpha	-1.5	0.008
54884	RETSAT	retinol saturase (all-trans-retinol 13,14-reductase)	1.6	0.008
5055	SERPINB2	serpin peptidase inhibitor, clade B (ovalbumin), member 2	-4.9	0.008
57568*	SIPA1L2	signal-induced proliferation-associated 1 like 2	-1.5	0.008
5207	PFKFB1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1	1.9	0.008
60559*	SPCS3	signal peptidase complex subunit 3 homolog (S. cerevisiae)	-1.6	0.008
9197*	SLC33A1	solute carrier family 33 (acetyl-CoA transporter), member 1	-1.5	0.008
3991	LIPE	lipase, hormone-sensitive	1.6	0.008
26064*	RAI14	retinoic acid induced 14	-1.6	0.008
8542*	APOL1	apolipoprotein L, 1	-1.6	0.008
374969	CCDC23	coiled-coil domain containing 23	1.5	0.008
8639	AOC3	amine oxidase, copper containing 3 (vascular adhesion protein 1)	1.6	0.008

ENTREZ	SYMBOL	Name	Fold Change	q-value
11098	PRSS23	protease, serine, 23	-1.7	0.008
2822	GPLD1	glycosylphosphatidylinositol specific phospholipase D1	1.7	0.008
8659	ALDH4A1	aldehyde dehydrogenase 4 family, member A1	1.8	0.008
4718	THRSP	thyroid hormone responsive (SPOT14 homolog, rat)	1.8	0.008
55024*	BANK1	B-cell scaffold protein with ankyrin repeats 1	1.6	0.008
6782*	HSPA13	heat shock protein 70kDa family, member 13	-1.8	0.008
65983	GRAMD3	GRAM domain containing 3	-1.8	0.008
4137	MAPT	microtubule-associated protein tau	1.6	0.008
1009	CDH11	cadherin 11, type 2, OB-cadherin (osteoblast)	-2.0	0.008
10130*	PDIA6	protein disulfide isomerase family A, member 6	-1.5	0.008
51602*	NOP58	NOP58 ribonucleoprotein homolog (yeast)	-1.6	0.008
81539	SLC38A1	solute carrier family 38, member 1	-2.4	0.008
51716	CES1	carboxylesterase 1 (monocyte/macrophage serine esterase 1)	2.2	0.008
9643*	MORF4L2	mortality factor 4 like 2	-1.5	0.008
666	BOK	BCL2-related ovarian killer	1.6	0.008
9945	GFPT2	glutamine-fructose-6-phosphate transaminase 2	-2.4	0.008
55254*	TMEM39A	transmembrane protein 39A	-1.5	0.008
22915	MMRN1	multimerin 1	-3.8	0.008
84293	C10orf58	chromosome 10 open reading frame 58	1.6	0.008
64757	MOSC1	MOCO sulphurase C-terminal domain containing 1	1.6	0.008
64805*	P2RY12	purinergic receptor P2Y, G-protein coupled, 12	1.6	0.008
91607	SLFN13	schlafen family member 13	-1.5	0.009
220	ALDH1A3	aldehyde dehydrogenase 1 family, member A3	-2.3	0.009
212*	ALAS2	aminolevulinate, delta-, synthase 2	1.7	0.009
10962	MLLT11	myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11	-2.2	0.009
358*	AQP1	aquaporin 1 (Colton blood group)	-1.5	0.009
23612*	PHLDA3	pleckstrin homology-like domain, family A, member 3	1.5	0.009
6578	SLCO2A1	solute carrier organic anion transporter family, member 2A1	-1.7	0.009
286753*	TUSC5	tumor suppressor candidate 5	1.5	0.009
5271*	SERPINB8	serpin peptidase inhibitor, clade B (ovalbumin), member 8	-1.7	0.009
63924	CIDEC	cell death-inducing DFFA-like effector c	1.8	0.009
4189*	DNAJB9	DnaJ (Hsp40) homolog, subfamily B, member 9	-1.7	0.009
56265	CPXM1	carboxypeptidase X (M14 family), member 1	-1.7	0.009
58528*	RRAGD	Ras-related GTP binding D	1.5	0.009
262*	AMD1	adenosylmethionine decarboxylase 1	-1.5	0.009
222166	C7orf41	chromosome 7 open reading frame 41	1.6	0.009
338	APOB	apolipoprotein B (including Ag(x) antigen)	2.4	0.009
158295	MGC24103	hypothetical MGC24103	-1.5	0.009
1805*	DPT	dermatopontin	1.5	0.009

ENTREZ	SYMBOL	Name	Fold Change	q-value
10237*	SLC35B1	solute carrier family 35, member B1	-1.5	0.009
623	BDKRB1	bradykinin receptor B1	-3.0	0.009
5740	PTGIS	prostaglandin I2 (prostacyclin) synthase	-2.0	0.009
6272	SORT1	sortilin 1	1.7	0.009
1645	AKR1C2	aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)	2.1	0.009
5649	RELN	reelin	-1.6	0.009
6446	SGK1	serum/glucocorticoid regulated kinase 1	-1.9	0.009
51330	TNFRSF12A	tumor necrosis factor receptor superfamily, member 12A	-1.8	0.009
388403*	YPEL2	yippee-like 2 (Drosophila)	1.7	0.009
80704	SLC19A3	solute carrier family 19, member 3	1.5	0.009
5140	PDE3B	phosphodiesterase 3B, cGMP-inhibited	1.7	0.009
3036	HAS1	hyaluronan synthase 1	-1.7	0.009
1646	AKR1C1	aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)	2.3	0.009
1962	EHHADH	enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase	1.5	0.009
90355*	C5orf30	chromosome 5 open reading frame 30	1.6	0.009
283383	GPR133	G protein-coupled receptor 133	-2.1	0.009
4199	ME1	malic enzyme 1, NADP(+)-dependent, cytosolic	1.7	0.009
6366	CCL21	chemokine (C-C motif) ligand 21	-3.5	0.009
4023	LPL	lipoprotein lipase	1.6	0.009
6385	SDC4	syndecan 4	-2.5	0.009
84649	DGAT2	diacylglycerol O-acyltransferase homolog 2 (mouse)	1.6	0.009
80339*	PNPLA3	patatin-like phospholipase domain containing 3	1.6	0.009
783	CACNB2	calcium channel, voltage-dependent, beta 2 subunit	-1.7	0.009
7086	TKT	transketolase	1.5	0.009
63895*	FAM38B	family with sequence similarity 38, member B	-1.6	0.009
4883	NPR3	natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C)	1.8	0.009

Table 3

Biological processes associated with regional differences in the spontaneous term labor group.

Biological process	Term Size	DE Genes	Odds Ratio	q-value
response to external stimulus	951	74	2.7	< 0.001
retinal metabolic process	9	8	216.8	< 0.001
circulatory system development	739	61	2.6	< 0.001
regulation of complement activation	18	9	27.1	< 0.001
blood vessel morphogenesis	347	35	3.2	< 0.001
multicellular organismal process	4870	232	1.7	< 0.001
positive regulation of cellular component movement	283	30	3.3	< 0.001
anatomical structure formation involved in morphogenesis	846	61	2.2	< 0.001
regulation of cell motility	498	42	2.6	< 0.001
terpenoid metabolic process	63	13	7.2	< 0.001
retinol metabolic process	17	7	18.9	< 0.001
phototransduction, visible light	70	13	6.2	< 0.001
vasculature development	393	34	2.7	0.001
triglyceride catabolic process	25	8	12.7	0.001
positive regulation of signal transduction	905	60	2.1	0.001
glomerular filtration	19	7	15.8	0.001
neutral lipid catabolic process	29	8	10.3	0.002
regulation of inflammatory response	123	16	4.2	0.002
cell motility	461	35	2.5	0.002
positive regulation of cell-substrate adhesion	60	11	6.1	0.002
detection of light stimulus	86	13	4.9	0.003
acute inflammatory response	75	12	5.2	0.003
reproductive system development	321	28	2.6	0.004
striated muscle cell differentiation	164	18	3.4	0.005
regulation of hormone levels	122	15	3.9	0.005
tissue morphogenesis	498	37	2.2	0.005
death	1510	84	1.7	0.006
glycerolipid catabolic process	36	8	7.7	0.007
cellular response to jasmonic acid stimulus	3	3	Inf	0.008
positive regulation of phosphate metabolic process	776	50	1.9	0.008
receptor-mediated endocytosis	173	18	3.2	0.008
cellular developmental process	2884	140	1.5	0.008
protein activation cascade	49	9	6.1	0.009
tube development	407	31	2.3	0.010
urogenital system development	211	20	2.9	0.011
positive regulation vascular endothelial growth factor production	21	6	10.8	0.011
cell junction assembly	177	18	3.1	0.011

Biological process	Term Size	DE Genes	Odds Ratio	q-value
positive regulation of angiogenesis	102	13	4.0	0.011
response to lipid	607	41	2.0	0.012
positive regulation of macrophage derived foam cell differentiation	14	5	14.9	0.012
cell chemotaxis	181	18	3.0	0.013
single-organism process	634	29	2.7	0.013
response to oxygen-containing compound	948	56	1.8	0.013
terpenoid biosynthetic process	8	4	26.8	0.013
embryonic limb morphogenesis	106	13	3.8	0.014
regulation of response to stress	847	52	1.8	0.014
negative regulation of protein processing	234	21	2.7	0.014
positive regulation of epithelial cell proliferation	123	14	3.5	0.016
regulation of behavior	155	16	3.1	0.017
regulation of multicellular organismal development	1167	66	1.7	0.017
response to wounding	168	16	3.1	0.017
regulation of phosphorylation	1016	59	1.7	0.019
complement activation, alternative pathway	9	4	21.5	0.019
negative regulation of cardiac muscle tissue development	16	5	12.2	0.019
epithelium development	624	40	2.0	0.020
muscle cell migration	46	8	5.7	0.021
oxoacid metabolic process	849	51	1.8	0.022
regulation of transport	1300	71	1.6	0.023
regulation of leukocyte chemotaxis	72	10	4.4	0.023
positive regulation of focal adhesion assembly	17	5	11.2	0.023
regulation of protein metabolic process	152	15	3.1	0.024
small molecule metabolic process	1919	97	1.5	0.024
endothelial cell morphogenesis	10	4	17.9	0.025
negative regulation of heart growth	10	4	17.9	0.025
response to acid chemical	233	20	2.6	0.026
negative regulation of endopeptidase activity	150	15	3.0	0.028
establishment of localization	3464	158	1.4	0.028
cellular response to tumor necrosis factor	90	11	3.8	0.031
endodermal cell differentiation	39	7	5.9	0.034
retinoic acid biosynthetic process	5	3	40.3	0.034
protein secretion	352	26	2.2	0.035
cellular lipid metabolic process	480	32	2.0	0.035
cellular response to endogenous stimulus	836	49	1.7	0.035
regulation of cell adhesion	418	29	2.1	0.035
positive regulation of locomotion	193	17	2.7	0.035
appendage morphogenesis	123	13	3.2	0.035

Biological process	Term Size	DE Genes	Odds Ratio	q-value
negative regulation of muscle tissue development	29	6	7.0	0.035
positive regulation of cell proliferation	487	32	2.0	0.036
regulation of striated muscle tissue development	79	10	3.9	0.036
lung development	110	12	3.4	0.038
triglyceride biosynthetic process	53	8	4.8	0.039
positive regulation of mesenchymal cell proliferation	30	6	6.7	0.040
negative regulation of muscle organ development	30	6	6.7	0.040
positive regulation of leukocyte migration	81	10	3.8	0.042
neutral lipid biosynthetic process	54	8	4.7	0.042
peptide transport	248	20	2.4	0.043
peptide hormone secretion	195	17	2.6	0.045
inflammatory response	227	18	2.5	0.047
cell adhesion	493	31	2.0	0.047
response to toxic substance	129	13	3.0	0.047
positive regulation of MAPK cascade	236	19	2.4	0.047
regulation of cell-matrix adhesion	69	9	4.1	0.047
daunorubicin metabolic process	6	3	26.8	0.049
doxorubicin metabolic process	6	3	26.8	0.049

A list of the alternative splicing events associated with the regional differences of the adipose tissue of pregnant women not in labor

Table 4

ENTREZ	SYMBOL	Name	Exon ID ¹	Diff. FIRMA ²	p-value	q-value
5376	PMP22	peripheral myelin protein 22	887424	5.2	< 0.001	< 0.001
6711	SPTBN1	spectrin, beta, non-erythrocytic 1	103031	-5.1	< 0.001	< 0.001
25818	KLK5	kallikrein-related peptidase 5	960481	-4.6	< 0.001	< 0.001
85442	KNDC1	kinase non-catalytic C-lobe domain (KIND) containing 1	596822	-3.5	< 0.001	< 0.001
388610	TRNP1	TMF1-regulated nuclear protein 1	7232	-3.1	< 0.001	< 0.001
1612	DAPK1	death-associated protein kinase 1	538110	3.1	< 0.001	< 0.001
9201	DCLK1	doublecortin-like kinase 1	742860	-3.0	< 0.001	< 0.001
9214	FAIM3	Fas apoptotic inhibitory molecule 3	84252	-2.9	< 0.001	< 0.001
25891	PAMR1	peptidase domain containing associated with muscle regeneration 1	656516	2.9	< 0.001	< 0.001
3983	ABLIM1	actin binding LIM protein 1	619043	2.9	< 0.001	< 0.001
286204	CRB2	crumbs homolog 2 (Drosophila)	544486	-2.8	< 0.001	< 0.001
11343	MGLL	monoglyceride lipase	236116	-2.7	< 0.001	0.0017
25891	PAMR1	peptidase domain containing associated with muscle regeneration 1	656516	2.7	< 0.001	< 0.001
1674	DES	desmin	131889	-2.7	< 0.001	0.0068
10231	RCAN2	regulator of calcineurin 2	399076	2.6	< 0.001	< 0.001
23524	SRRM2	serine/arginine repetitive matrix 2	826444	-2.6	< 0.001	< 0.001
23524	SRRM2	serine/arginine repetitive matrix 2	826444	-2.5	< 0.001	< 0.001
157506	RDH10	retinol dehydrogenase 10 (all-trans)	491273	2.5	< 0.001	0.0017
85442	KNDC1	kinase non-catalytic C-lobe domain (KIND) containing 1	596819	-2.5	< 0.001	< 0.001
79804	HAND2	heart and neural crest derivatives expressed 2	298919	-2.4	< 0.001	< 0.001
65108	MARCKSL1		55081	-2.4	< 0.001	< 0.001
4071	TM4SF1	transmembrane 4 L six family member 1	240134	-2.4	< 0.001	0.006
4837	NNMT	nicotinamide N-methyltransferase	644508	-2.3	< 0.001	0.0099
51090	PLLP	plasma membrane proteolipid (plasmolipin)	855189	2.3	< 0.001	< 0.001
1674	DES	desmin	131895	-2.3	< 0.001	0.0028
152	ADRA2C	adrenergic, alpha-2C-, receptor	249900	-2.3	< 0.001	0.0037
81539	SLC38A1	solute carrier family 38, member 1	707206	2.3	< 0.001	< 0.001

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

ENTREZ	SYMBOL	Name	Exon ID ¹	Diff. FIRMA ²	p-value	q-value
57121	LPAR5	lysophosphatidic acid receptor 5	701054	-2.3	< 0.001	0.001
56920	SEMA3G	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3G	224606	-2.3	< 0.001	< 0.001
9945	GFPT2	glutamine-fructose-6-phosphate transaminase 2	359171	2.2	< 0.001	< 0.001
2627	GATA6	GATA binding protein 6	908232	-2.2	< 0.001	< 0.001
4824	NKX3-1	NK3 homeobox 1	506935	-2.1	< 0.001	< 0.001
3036	HAS1	hyaluronan synthase 1	960742	-2.1	< 0.001	< 0.001
5420	PODXL	podocalyxin-like	472183	-2.1	< 0.001	< 0.001
5420	PODXL	podocalyxin-like	472213	2.1	< 0.001	< 0.001
3339	HSPG2	heparan sulfate proteoglycan 2	52523	-2.1	< 0.001	0.0746
23555	TSPAN15	tetraspanin 15	582734	-2.1	< 0.001	< 0.001
23428	SLC7A8	solute carrier family 7 (cationic amino acid transporter, γ+ system), member 8	772193	-2.1	< 0.001	< 0.001
3913	LAMB2	laminin, beta 2 (laminin 5)	223487	-2.0	< 0.001	< 0.001
23428	SLC7A8	solute carrier family 7 (cationic amino acid transporter, γ+ system), member 8	772200	-2.0	< 0.001	< 0.001
89932	PAPLN	papilin, proteoglycan-like sulfated glycoprotein	763903	-2.0	< 0.001	< 0.001
255743	NPNT	nephronectin	263882	2.0	< 0.001	< 0.001